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ABSTRACT 
 
Role of Carrier Size, Hemodynamics and Hemorheology  
in the Efficacy of Vascular-Targeted Spherical Drug Carriers 
 
by 
 
Phapanin Charoenphol 
 
 
Chair: Omolola Eniola-Adefeso 
 
 
Spherical polymeric particles in the submicron down to tens nanometers size 
range are extensively proposed for use as vascular-targeted drug carriers (VTDCs); 
however, very limited studies have explored their capacity to efficiently localize and 
adhere to the vascular wall. The studies presented in this dissertation are focused on 
characterizing the role of particle size, blood flow dynamics (hemodynamics) and blood 
cells (hemorheology) on dictating the targeting (localization and binding) efficiency of 
VTDCs at the vascular wall in physiological human bulk blood flow via in vitro parallel 
plate flow assays.   
 xv 
The presented results show that the binding efficiency of VTDCs is a function of 
particle size in all flow types (i.e. laminar, pulsatile and recirculating flow) and is 
strongly modulated by the presence of red blood cells (RBCs). Specifically, the migration 
of RBCs away from the wall under shear flow creating the RBC-free layer (CFL) at the 
wall vicinity where leukocytes and microspheres are disproportionally concentrated 
whereas nanospheres tend to get trapped within the RBC core. The binding of localized 
particle is either enhanced or hindered depending on the ratio of particle size to the CFL 
width that can vary with the volume fraction of RBCs (% Hct), blood vessel size and wall 
shear rate. White blood cells (WBCs) tend to hinder microsphere binding due to their 
collision with bound particles associated with their tethering on the vascular wall, which 
increases the drag force on particles leading to particle removal. Overall, the presented 
results suggest that intermediate-size microspheres, 2–5 µm, not nanospheres or large 
microspheres, are the optimal particle sizes for targeting the wall from human blood flow 
in medium to large-sized blood vessels relevant in several cardiovascular diseases. The 
relevance of the presented in vitro results were valid with ex vivo model of mouse blood 
where it is found that the subtle differences in RBC sizes and hemorheology among 
various animal models utilized in drug delivery research can differently manipulate the 
particle dynamics and their eventual adhesion in blood flow; thus, raising the awareness 
of possible result deviation from animal models to human. 
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CHAPTER 1  
 
INTRODUCTION 
 
1.1 Background and Significance 
Targeted drug delivery is a non-invasive process by which drug carriers are guided 
to deliver encapsulated/attached therapeutic agents at a targeted location, commonly via 
intravenous route. This approach has gained interest over conventional drug treatment, 
i.e. oral administration in which medications are distributed throughout the systemic 
blood circulation, by providing 
 (1) An increased drug efficacy at the targeted sites associated with the ability of 
drug carriers to sustain drug release over time, which can increase patient’s 
compliance and  
(2) A minimized deleterious side effect to other healthy tissues often associated 
with the systemic delivery of highly potent drugs.  
Targeted drug delivery is often achieved via two different mechanisms: passive 
and active targeting. Passive targeting is achieved via the localization and entrapment of 
nanocarriers into target sites having a unique physical morphology, e.g. the enhanced 
permeability and retention effect (EPR) associated with vascular wall in cancer. In this 
phenomenon, the fast production of blood vessels in response to tumor growth results in 
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the abnormal structure of the vasculature with leaky tight junctions existing between 
endothelial cells. This vasculature architecture coupled with an ineffective lymphatic 
drainage allows the accumulation of nano-size particle to be trapped and retained inside 
the tissue without being filtered out due to lacking of lymphatic system [1, 2]. On the 
other hand, active targeting requires the specific interactions between receptors at the 
targeted sites and their recognitive ligands. Due to its specificity, this latter mechanism 
offers controllable and precise targeting and is widely applicable for treating several 
human diseases [2-4]. 
The vascular (blood vessel) wall has become a promising focus for targeted drug 
delivery since the endothelium (a cell monolayer lining the luminal surface of blood 
vessels) is readily accessible for intravenously administered targeting agents and due to 
the better understanding in the active role of endothelium plays in the physiological and 
pathological processes such as angiogenesis and inflammation [5, 6]. Recently, vascular 
targeting has been explored for localized delivery of therapeutics in several diseases 
including cancer as well as in pulmonary and cardiovascular diseases [7, 8]. This 
dissertation, however, is focused on vascular-targeted drug delivery via inflammation for 
treating chronic inflammatory diseases, particularly coronary artery disease (CAD) that 
results from atherosclerosis. 
Due to the increasing incidence of high fat diet, sedentary lifestyles and smoking 
habits, recently, cardiovascular diseases including atherosclerosis remain the major cause 
of morbidity and mortality in the world [9, 10]. Current therapies for atherosclerosis 
include routine oral static drug and invasive bypass surgery. Major coronary events can 
still occur for patients who have underdone intense statin treatment [11] and surgical 
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interventions cannot prevent reoccurrence. Due to such limitations, development of an 
alternative therapy that can eliminate the surgical need and improve the drug efficacy 
relative to statin treatment is necessary. Targeted drug delivery via inflamed vascular 
wall is one of the promising treatments for atherosclerosis since inflammation is involved 
in all stages of atherosclerotic plaque development and progression [12]. 
1.1.1 Inflammation 
Inflammation is a natural process by which living tissue responds to harmful 
stimuli resulting from physical injury or destructive microorganism. The presence of 
foreign antigens in the body triggers the recruitment of white blood cells (WBCS) or 
leukocytes from blood flow to the injured site, leading to acute inflammation – an initial 
positive response from the body. However, the failure to shut down inflammatory 
response can lead to the continuous recruitment of leukocytes, resulting in chronic 
inflammation, involved in the progression of several human diseases.  
Neutrophils are the most abundant leukocytes in blood and the most active in 
inflammation. During the inflammation process, in attempting to remove harmful stimuli 
and initiate the healing process, neutrophils are recruited from the blood stream to 
accumulate at the injured site within minutes of inflammatory signal [13]. Initially, 
neutrophils are tethered and then transient to rolling adhesion along the inflamed vascular 
wall via their surface-expressed carbohydrate ligand, PSGL-1 (P-selectin Glycoprotein 
Ligand 1), interacting with selectins, i.e. P- and E-selectin, upregulated by endothelium 
of the vascular wall in response to inflammatory stimuli. Subsequently, in close 
proximity to the vessel wall, integrins membrane proteins, i.e. macrophage-1 antigen 
(Mac-1) and lymphocyte function-associated antigen-1 (LFA-1), present on rolling 
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neutrophil, are activated by chemoattractant released from the inflamed endothelium. 
Upon activation, integrins interact with intracellular adhesion molecule-1 (ICAM-1) 
and/or vascular adhesion molecule-1 (VCAM-1) upregulated on the endothelial wall 
leading to leukocyte firm adhesion. Afterwards, neutrophils creep and transmigrate via 
junction adhesion molecules (JAMs) or platelet endothelial cell adhesion molecule 
(PECAM-1) into the underlying injured tissue to remove the harmful stimuli. The 
schematic of leukocyte adhesion cascade is shown in Fig. 1.1 [14].  
Due to this specific and well-ordered leukocyte adhesion cascade occurred at the 
injured vascular wall during inflammation, it provides an avenue for vascular-targeted 
drug delivery, particularly for treating chronic inflammatory diseases, by imitating the 
leukocytes to a vascular-targeted drug carrier (VTDC). 
 
 
Figure 1.1 White blood cell (or leukocyte) adhesion cascade during inflammation [14]  
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1.1.2 Vascular-Targeted Drug Carrier (VTDC) 
To design an effective vascular-targeted drug carrier (VTDC), several criteria 
need to be considered including targeting, hemodynamics and carrier physical properties. 
1.1.2.1 Targeting Property 
The ability of drug carrier to localize therapeutic agents selectively to a diseased 
location is achieved by decorating the drug carrier surface with counteract ligands of 
receptors expressed at the targeted sites. For instances, selectins, ICAM-1 and VCAM-1 
are attractive receptors to target on inflamed endothelium [15, 16]. The common counter-
ligands for selectins include PSGL-1, sialyl-lewis x (sLex), sialyl-lewis A (sLeA, a 
sialylated fucosylated tetrasaccharide naturally found on neutrophil surface) and HuEP, a 
humanized murine selectin blocking antibody [17, 18]. Due to the high association rate of 
these ligands associated with selectins, the ligand-bearing carrier can be easily captured 
to the wall via selectins under high shear flow; meanwhile, the carrier also tends to roll 
along endothelium or readily be detached if shear force interacting on the particle is 
larger than their adhesive force [19]. Monoclonal antibodies are common ligands 
proposed against ICAM-1 and VCAM-1. Due to the low association rate of these ligand-
receptors, antibody-coated particle can only interact with these receptors under low shear 
force, though these particles can withstand the higher drag force once adherence due to 
their low dissociation rate [19].  
Targeting ligands are generally employed on VTDC via avidin-biotin chemistry 
[17] or other linkages, e.g. polyethylene glycol (PEG), commonly used for prolong 
particle circulation time in vivo [20]. Ligands can be used alone or in conjunction with 
other ligands, i.e. multiple receptors targeting. In general, targeting inflammation via 
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selectins is preferable than ICAM-1 since a basal level of ICAM-1 is present on 
endothelium in healthy tissues [19]. Thus, targeting via ICAM-1 alone may not 
differentiate between normal and diseased tissues. Overall, several works have shown 
that these leukocyte-mimetic drug carriers can recognize and vividly target the inflamed 
tissue both in vitro and in vivo [17, 18, 21]. 
1.1.2.2 Hemodynamics Property 
Prior to their interaction with the target sites, the drug carriers must be able to 
circulate in blood flow and localize through the dense population of blood cells to the 
vascular wall vicinity. Hemodynamics describes the movement of blood cells in the 
circulatory system, which is imposed by different flow dynamics that can vary with the 
size, location and structure of blood vessels [22, 23].  Previous works have shown that 
red blood cells (RBCs), the most abundant blood cells, play important roles on initiating 
and promoting the binding of white blood cells and platelets during inflammation and 
hemostasis processes, respectively [24, 25]. Thus, it is likely that RBCs would also 
significantly manipulate the behavior of drug carriers in blood flow. Additionally, shear 
force associated with blood flow also governs all stages of drug carrier margination, i.e. 
manipulate the interaction with RBCs and the diffusion and convection of particles to the 
wall proximity, control the ligand-receptor binding rate on endothelium and dictate the 
particle adherence fate at the vascular wall [26]. Overall, hemodynamics is an important 
factor that prescribes the localization and the binding of drug carriers at the target site. 
1.1.2.3 Physical Property 
 Several particle types, such as micelles, dendrimers, immunoliposome and 
polymeric particles, have been commonly proposed for use as VTDCs and their 
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application in various diseases has been extensively reviewed elsewhere [27, 28]. Due to 
their simple fabrication process, high drug loading capacity, tunable carrier degradation 
rate and hence controllable drug release profile, polymeric spheres are typical and prefer 
for use as VTDCs [29]. The particle can be fabricated via various simple procedures such 
as oil-in-water emulsion (O/W) method where therapeutic agents are encapsulated inside 
the polymer matrix during the process [30]. Altering the material or composition of this 
polymer can generally control the rate of drug release and carrier degradation [29]. 
Biodegradable and biocompatible polymers such as poly (lactic–co-glycolic acid) 
(PLGA) and poly (caprolactone) (PCL) are desirable for in vivo use since these polymers 
can break down in physiological environment into disintegrated polymers that evoke little 
or no immune response [30, 31]. 
 In addition to the type of drug carriers, particle shape and size are parameters that 
also play an important role in drug carrier fate. Though, many particle shapes, including 
rod, disc and worm-like shapes, has recently gained interest for use as VTDCs due to 
their ability to avoid immune clearance, which enhance their circulation time in vivo [32, 
33], spherical particles are still widely used for targeting therapeutics to the vascular wall. 
This is likely due to their ease in fabrication and well-defined model for hydrodynamic 
interactions. Spherical particles sized in the submicron down to tens of nanometer range 
have been extensively proposed as VTDCs due to their ability to navigate through the 
microvasculature without treat of occlusion in capillaries, the smallest blood vessels (5-7 
µm in diameter in humans) and are less vulnerable to immune clearance [34, 35]. 
However, in addition to their circulation ability, the ideal drug carriers must also 
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 (1) Be able to navigate through the dense blood cells to reach the blood vessel 
wall, and  
 (2) Remain in the adhesive state on the endothelium long enough to release their 
drug cargo or be internalized (get engulfed by the cells).  
These two constraints constitute the binding efficiency of vascular-targeted carriers.  
 
Particles Target Sites Experimental Set Up 
6 µm PLGA [36] Inflammatory molecules 
coated substrate 
In vitro flow adhesion assay in saline 
3.4 µm Microbubbles 
[37]  
Inflamed endothelial cells In vitro flow adhesion assay in saline 
270 nm PLGA [38] Inflamed endothelial cells In vitro static adhesion assay in saline 
4.5 µm Iron Oxide 
[39] 
Aortic root of ApoE-/- mice In vivo via local left ventricular 
injection  
2 µm PS [40] Aorta of ApoE-/- mice In vivo via local jugular injection  
17 nm Micelles [41] Plaques lesion (stage V) of 
ApoE-/- mice 
In vivo via tail vein injection  
60 nm PLA [42] Mouse injured vasculature In vivo via tail vein injection 
 
Table 1.1 Vascular-targeted carrier used in imaging and therapeutic delivery, particularly 
targeting to inflamed endothelial cells in vitro flow assay and to atherosclerotic 
plaque in vivo. 
 
In existing works, a wide size range of spherical particles from nano- up to 
micron scale have been employed for VTDC, as summarized in Table 1.1. Nevertheless, 
these works mainly described the ability of VTDCs to successfully localize to the 
targeted site in simple buffer flow in vitro or in vivo while neglecting to determine their 
overall binding efficiency, i.e. the total numbers of VTDCs reaches the targeted area 
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relative to the total feed. Though nanoparticles may be preferable to use in vivo, due to 
their ease in circulation, it is not clear how the binding efficiency of these particles relate 
to other particle size. To date, very limited work has evaluated the role of size on 
prescribing the binding efficiency of spherical drug carriers to the vascular wall (Table 
1.2). 
 
Particle Size Media WSR Particle Adhesion Trend 
5-20 µm [26] Saline 75-600 s-1 (1) At low WSR: size independent 
(2) At high WSR: small particle favors 
adhesion 
0.1-20 µm 
[43] 
Viscous Saline 
(µ=10 cP) 
1 s-1 (1) Particle size smaller or larger than a 
critical particle size (~ 300 nm) would 
have a propensity to the wall. 
(2) A critical particle size varies 
with particle density. 
0.05-10 µm 
[44] 
Saline 7.75 s-1 Large particles have higher adhesion. 
0.96-5.2 µm 
[45] 
Washed blood 
(15% Hct 
RBCs in 
Saline) 
430-1630 s-1 Only particle larger than 2 µm display 
near-wall excess (no adhesion). 
 
Table 1.2  Summary of works investigating the role of size on spherical particle adhesion 
under shear flow. 
 
As summarized in Table 1.2, the role of size on the particle binding at the wall are 
still inconclusive and many of the existing work have not been done in physiological 
manner. Though the computational work from Decuzzi et al and the experimental work 
from Gentile et al claimed that large microspheres had higher propensity for adhesion 
[43], Patil et al suggested that small particles demonstrated higher binding, particularly at 
high WSR relevant in physiological conditions [26]. Nevertheless, these works were 
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conducted in saline while neglecting red blood cells (RBCs) that play a significant 
influence on particle margination as indicated by their important role on the binding of 
white blood cells and platelets [24, 25]. Eckstein and his colleagues studied particle 
localization (no adhesion) in the presence of RBCs (15% Hct, the volume fraction of 
RBCs in blood) and suggested that particle larger than 2 µm (up to 5 µm) tend to 
accumulate in the wall proximity [45]. However, the particle localization may not 
absolutely translate to their binding trend in vivo, since the average percent of hematocrit 
in whole blood is about 40-45% Hct and the level of hematocrits have been shown to 
effect the binding density of blood cells [24]. Therefore, this study aims to elucidate the 
potential role of hemodynamics and particle size in prescribing the binding efficiency of 
vascular-targeted drug delivery in physiological blood flow.  
Initially, the particle binding experiments will be observed in simple reconstituted 
blood flow consisting of plasma and RBCs (i.e. blood devoid of WBCs and platelets). 
The physiological range of shear rate and size of blood vessels and different flow types, 
i.e. laminar (commonly exists in vein and microcirculation), pulsatile and recirculating 
flow (generally occurs in medium to large-sized arteries and bifurcation area) 
encountered in vivo will be incorporated in this study.  
Moreover, this work would further investigate the potential influence of WBCs 
and platelets on the adhesion of VTDC by conducting the flow adhesion experiments in 
whole blood flow. To date, no work, to my knowledge, has been presented to elucidate 
the interplay between these blood cells and particles especially on dictating the particle 
margination. Instead, most of previous works have been focused on the interaction of 
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particle to blood cells that may affect cells functionality, i.e. study the particle 
biocompatibility [27, 46].  
In another aspect, due to the potential significant role of RBCs, the subtle 
differences of RBC size varied with different animal models [47] may possibly have 
influences on particle adhesion. To date, only few investigators have realized differences 
between animal and human blood rheology that could provide the great variation on the 
margination of blood cells and particle.  Indeed, in one work, the significant differences 
of platelet adhesion in several mammalian whole bloods were observed [48] and these 
differences could be explained by the variation of animal RBC size, as suggested by 
Aarts et al [49]. However, it is still not clear how different RBC size along with other 
blood cell components would affect the binding efficiency of vascular-targeted drug 
carrier (VTDC) with different sizes. Thus, this dissertation would attempt to seek for the 
clarification.   
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1.2 Organization of the dissertation 
This dissertation thesis consists of seven chapters. 
Chapter 1 briefly introduces background and significance, literature review and 
the scope of my experimental works.  
Chapter 2 indicates the source of materials and describes the experimental 
procedures employed in Chapters 3 to 6.  
Chapter 3 discusses the role of particle size in dictating the binding efficiency of 
vascular-targeted drug carrier (VTDC) in in vitro laminar flow assay. Specifically, sLeA- 
or aICAM- conjugated polymeric spherical particles with size ranging from 200 nm to 10 
µm in diameter were used as VTDC. Polystyrene particles were preferable to 
biodegradable particles due to their uniform size distribution, which enables repeatable 
and consistent experiments. The adhesion of these particles in saline and reconstituted 
laminar blood flow (plasma and red blood cell) was examined via a parallel plate flow 
chamber (PPFC) with flow over a monolayer of activated human umbilical vein 
endothelial cells (HUVECs). This experimental setup is commonly used for an in vitro 
model of inflamed endothelial lining of blood vessels and is employed throughout the 
dissertation. Particle binding in typical ranges of shear rate and blood vessel size found in 
vivo were incorporated in this experimental study. 
Chapter 4 investigates the role of particle size on the efficiency of VTDC in 
targeting the particular disease, i.e. atherosclerosis. Specifically, particle binding was 
observed in disturbed reconstituted blood flow (i.e. pulsatile and recirculating flow), 
which is a typical blood flow existed in medium to large sized arteries and at bifurcation 
area where the deposition of atherosclerotic plaque usually occurred. 
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Chapter 5 elucidates the significance of blood cells, including red blood cells, 
white blood cells (leukocytes) and platelets, on the behavior of particle with different 
sizes in blood flow. The binding of particles was investigated in various blood 
compositions, i.e. reconstituted blood with distinct volume fraction of red blood cell (% 
hematocrit), whole blood (WB), platelet-depleted blood (PDB) and leukocyte-depleted 
blood (PDB), allowing us to understand the role of blood cells on particle localization 
and adhesion in blood flow. 
Chapter 6 examines the potential effect of red blood cell size and hemorheology, 
which vary with different animal models, on the particle binding efficiency. In particular, 
particle binding was studied in washed blood flow (RBCs suspended in saline) with 
various sizes of RBCs, obtained from human and several animals including mouse, pig, 
cow and goat. In addition, the experiments were further conducted in human and mouse 
whole blood to study the possible contribution of plasma and other blood components. 
The results from this chapter would raise awareness of the possible difference in results 
obtained from animal models to represent human.  
Chapter 7 draws the conclusion and summarizes the significant findings from this 
dissertation to the field of study. Several topics are also proposed for future research. 
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CHAPTER 2  
MATERIALS AND METHODS 
 
This chapter describes the procedures used for all experimental studies in this 
dissertation. In general, particle (vascular-targeted drug carrier) adhesion experiments 
were conducted in a parallel plate flow chamber with controlled wall shear rate and flow 
types at body temperature. The binding of particle on activated endothelial cells in blood 
flow was observed and analyzed via the inverted light microscope equipped with a digital 
camera. 
2.1 Materials 
Interleukin 1-β (IL1-β) was purchased from Fitzgerald Industries International 
(Concord, MA). Medium 199, penicillin, streptomycin, fungizone and HEPES buffer 
were purchased from Invitrogen (Carlsbad, CA). Fetal and bovine calf serums (FCS and 
BCS) were purchased from Hyclone (Logan, UT). Endothelial cell growth supplement 
(ECGS) was purchased from BD Biosciences (San Jose, CA). NeutrAvidin was 
purchased from Pierce Biotechnology, Inc. (Rockford, IL). Biotinylated, multivalent 
sialyl Lewis A (sLeA) carbohydrate was purchased from GlycoTech (Gaithersburg, MD). 
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Biotinylated human ICAM-1 antibody (aICAM) Clone HA58 and Clone BBIG-I1 were 
purchased from eBioscience (San Diego, CA) and R&D Systems (Minneapolis, MN), 
respectively. Biotinylated human VCAM-1 antibody (aVCAM) Clone 1G11B1 was 
purchased from Abcam (Cambridge, MA). Carboxylated-functionalized, avidin-
functionalized polystyrene spheres, Quantum PE and FITC MESF calibration beads were 
purchased from Bangs Laboratories Inc. (Fishers, IN). Biotin-4-fluorescein was 
purchased from Molecular Probe (Carlsbad, CA). PE-labeled anti-human CLA was 
purchased from Miltenyi Biotech (Auburn, CA). PE conjugated Rat IgG isotype control 
and PE conjugated anti-Mouse IgG were purchased from BD Pharmingen (San Diego, 
CA). Fluorescein conjugated goat anti-mouse IgG was purchased from Jackson 
ImmunoResearch Laboratories Inc. (West Grove, PA). Fluorescein conjugated anti-hE-
selectin/CD62E, anti-hVCAM/CD106 and anti-hICAM/CD54 were purchased from R&D 
Systems (Minneapolis, MN). Isolated animal red blood cells (pig, cow and goat) were 
purchased from Lampire Biological Laboratories (Pipersville, PA). Dextran (MW 
250,000) was purchased from MP Biomedicals (Solon, OH). Glutaraldehyde was 
purchased from Polysciences (Warrington, PA). Ethylenediaminetetraacetic acid (EDTA) 
was purchased from Boston Bioproducts Inc. (Worcester, MA). Dulbecco’s phosphate 
buffered saline (DPBS), Bovine Serum Albumin (BSA) and all other chemical/cell 
reagents were purchased from Sigma Aldrich (Saint Louis, MO). 
2.2 Particle Avidin Attachment 
NeutrAvidin protein was covalently coupled to carboxylate-modified polystyrene 
spheres via carbodiimide (EDAC) chemistry as described in [1]. Briefly, 800 µL of 5 
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mg/mL NeutrAvidin in 50 mM MES buffer (pH 3.8) was added to sphere pellets (5.6x108 
beads for 5.75 µm) and incubated on an end-to-end rotor for 15 mins at room 
temperature. Subsequently, 800 µL of 75 mg/mL EDAC in 50 mM MES buffer was 
added to the avidin-particle mixture and pH was adjusted to 8.5 via 1M NaOH.  After an 
overnight incubation (~20 hrs), the reaction was quenched via 30 mins incubation with 
glycine at 100 mM (final concentration in the particle mixture). NeutrAvidin conjugated 
spheres were washed twice and resuspended in 50 mM PBS (50 mM sodium dihydrogen 
phosphate and 50 mM sodium phosphate dibasic, pH 7.4). Spheres were kept at 4oC until 
use. 
2.3 Preparation of Vascular-Targeted Spheres 
  Avidin-coated spheres, 0.20, 0.51, 2.07, 5.72, 9.77 and 15.14 µm in size, obtained 
commercially or derived in the lab were conjugated with biotinylated Sialyl Lewis A 
(sLeA, a carbohydrate ligand that binds to selectins) or human ICAM-1 antibody 
(aICAM) (Clone HA58 for Chapter 3 or Clone BBIG-I1 for Chapter 4) or human 
VCAM-1 antibody (aVCAM) (Clone 1G11B1), as previously described [2]. Briefly, 
avidin-coated spheres were incubated with the targeting ligands in 50 mM PBS with 1% 
BSA on an end-to-end rotor for 45 mins at room temperature. Concentration of ligands in 
solution used for each particle size was varied to ensure the same ligand surface density 
for all spheres. After conjugation, spheres were washed twice in DPBS+ (DPBS, 1% 
BSA, Ca2+, Mg2+ pH=7.4) and resuspended in the desired flow buffer.  
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2.4 Ligand Site Density Determination 
Ligand-conjugated microspheres were incubated with 10 µg/mL of PE conjugated 
anti-human CLA (HECA-452), Fluorescein conjugated goat anti-Mouse IgG and PE 
conjugated anti-Mouse IgG for labeling sLeA, aICAM and aVCAM-coated spheres, 
respectively, in DPBS+ for 20 mins on an end-to-end rotor at room temperature. Spheres 
were then washed twice in DPBS+, and fluorescence intensities were measured via BD 
FACSCalibur. Site density determination was as described in [3].  Briefly, the intensities 
were converted to ligand surface density via a calibration curve relating the fluorescence 
peaks of Quantum Standard Beads to their molecules of equivalent soluble fluorochrome 
(MESF); fluorophor to protein (F/P) ratio between the primary antibody (PE) to protein 
was assumed to be 1:1. A site density of approximate 1000, 4700 and 4500 sites/µm2 
were used for in vitro experiments with sLeA, anti-ICAM-1 and anti-VCAM-1-coated 
spheres, respectively. 
2.5 Preparation of Endothelial Cell (EC) Monolayer 
Human umbilical vein endothelial cells (HUVECs) were harvested from fresh 
umbilical cords obtained from Mott children’s hospital (Ann Arbor, MI), as previously 
described [4].  Briefly, HUVEC were harvested from human umbilical veins via the well-
known collagenase perfusion method [5], pooled and cultured in tissue culture flasks 
pretreated with gelatin (0.2% w/v).  The growth medium comprised of M199 
supplemented with 10% FBS, 10% BCS, 1% penicillin-streptomycin, 1% fungizone, 1% 
HEPES buffer, 1 µg/ml heparin, and 50 µg/ml endothelial cell (EC) growth supplement.  
For flow experiments, pooled HUVEC were subcultured onto 30 mm glass cover slips 
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pretreated with 1% w/v gelatin cross-linked with 0.5% glutaraldehyde [6].  HUVEC on 
coverslips were kept at 37°C in a humidified 5% CO2 incubator until confluent. 
Confluent HUVEC monolayers were activated with IL-1β at 1 ng/mL for 4, 8 or 24 hrs 
before use for experiments with sLeA-, aVCAM- or aICAM-spheres, respectively. To 
confirm E-selectin, ICAM-1 and VCAM-1 expression, activated HUVECs were detached 
from glass coverslip with 0.25% trypsin and resuspended in DPBS at 4oC. Detached cells 
were then incubated with 10 µg/mL of fluorescein (FITC)-conjugated anti-hE-selectin 
antibody, anti-hICAM antibody and anti-hVCAM antibody for 30 mins at 4oC.  Cell 
fluorescence intensity was measured via flow cytometry. Each cell monolayers was used 
only once. 
2.6 Preparation of Whole Blood (WB), Reconstituted Blood (RB), 
Washed Blood, Platelet-Depleted Blood (PDB) and Leukocyte-
Depleted Blood (LDB) 
Fresh human blood was obtained via venipuncture according to a protocol 
approved by the University of Michigan Internal Review Board and in line with the 
standards set by the Helsinki Declaration. Venous blood was collected from healthy adult 
donors into a 60 ml syringe containing acetate-citrate-dextrose, ACD, as anticoagulant. 
This anticoagulated whole blood (WB) was either used in flow experiments as is or with 
6%wt dextran solution (250 MW at 1.4 mL/10 mL of blood) added in for some control 
experiments (WB+D, used in Chapter 5).   
To prepare reconstituted blood (cell-free plasma and RBCs, used in Chapter 3 and 
4) and human washed blood (saline and RBCs, used in Chapter 6), a 6 % wt dextran-250 
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mixture was sit upright at room temperature for ~ 2 hrs allowing RBCs to sediment to the 
bottom layer from the leukocyte-platelet rich plasma at the top layer. Cell-free plasma 
was obtained by centrifugation of the top layer at 2500 g for 10 mins to remove platelets 
and leukocytes. RBCs collected from the bottom layer was washed with DPBS and 
centrifuge at 500 g for 10 mins prior to resuspending in the cell-free plasma or DPBS+ at 
desired percent of hematocrit (% Hct), i.e. volume fraction of RBCs, to obtain the 
reconstituted blood (RB) or washed blood, respectively. For instances, 40% Hct 
reconstituted blood was prepared from the mixture of 40 % v/v of RBCs with 60% v/v of 
the cell-free plasma.  
To obtain platelet-depleted blood (PDB, used in Chapter 5), the anticoagulated 
whole blood was centrifuged with zero break at 300 g for 10 mins twice to obtain the 
separation of platelet-rich plasma (PRP) at the top layer and blood cells at the bottom 
layer. Subsequently, platelets were removed from PRP by centrifugation at 2500 g for 10 
mins and the supernatant, i.e. platelet-poor plasma, was recombined with blood cells to 
obtain PDB. 
To prepare leukocyte-depleted blood (LDB, used in Chapter 5), a 6% wt dextran-
250 solution (1.4 mL/10 mL of blood) was added into the anticoagulated whole blood 
and red blood cells (RBCs) were allowed to sedimentation to the bottom layer for 2 hrs at 
room temperature. The top layer containing platelets and WBC in plasma was then 
centrifuged at 300 g for 8 mins to remove WBCs. LDB was obtained from the 
recombination of WBC-removed supernatant with RBCs.  
For experiments studying the physical effect of WBC (Chapter 5), poly (lactic-co-
glycolic) acid (PLGA) polymeric spheres fabricated via oil-in-water method with size 
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ranging from 6 – 13 µm (average size = 8 µm) were used as non-functional WBCs (with 
no adhesive function). After fabrication, the PLGA spheres were incubated with DPBS+ 
and 1% BSA for 2 hrs to block non-specific binding of spheres to the endothelial cells. 
The spheres with concentrations of 4x106 particles/mL of blood (the normal 
concentration of WBC in whole blood) were then added into LDB to represent the non-
functional WBCs in whole blood. 
To prepare pig, cow and goat washed blood (used in Chapter 6), isolated pig, cow 
and goat RBCs were obtained commercially  (Lampire Biological Lab, Pipersville, PA) 
and washed in DPBS once to remove the excess anticoagulant (at 1000 g 30 mins) prior 
to suspension in DPBS+ with 1% BSA to 40% Hct.   Mouse whole blood was collected 
from surplus mice, generously provided by the breeding colony of Unit of Laboratory 
Animal Medicine (ULAM). All animal procedures were approved by ULAM and 
University Committee on Use and Care of Animals (UCUCA) at the University of 
Michigan. Briefly, blood was drawn from anaesthetized mice by a cardiac puncture into a 
syringe containing heparin as an anticoagulant. Pooled mouse whole bloods were 
centrifuged at 1000 g for 30 mins to collect mouse RBCs. However, it is difficult to 
isolate pure mouse RBCs from mouse whole blood by centrifugation. Thus, the pellets 
from this spin contained all mouse blood cells including RBCs, WBCs and platelets. 
Isolated mouse blood cells were then washed in DPBS once to minimize the excess 
anticoagulant and/or plasma constituents and were spun down at 1000 g for 30 mins. 
These RBCs were then resuspended in DPBS+ with 1% BSA at 40% Hct to yield mouse 
washed blood.  
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For human and animal whole blood experiments (used in Chapter 6), mouse whole 
blood containing heparin and human whole blood containing ACD were stored at 4oC 
overnight before used. To prepare plasma-removed blood (PRB), human and mouse 
whole blood were centrifuged down at 600 g for 30 mins to remove plasma. All blood 
cells were then resuspended in DPBS+, at the same % hematocrit as originally in whole 
blood.  
All blood components were kept at 37oC until used. 
2.7 Flow Adhesion Experimental Set Up 
A circular parallel plate flow chamber (PPFC) equipped with a straight (for laminar 
and pulsatile flow) or vertical step channels (for recirculating flow) (GlycoTech, 
Gaithersburg, MD) were used for in vitro flow adhesion assays.  Specifically, a silicon 
rubber gasket with rectangular cutout was attached to a flow chamber deck. An activated 
HUVEC monolayer cultured on a glass coverslip was placed over the gasket and 
vacuum-sealed to the flow deck such that the HUVEC monolayer formed the bottom 
substrate of the flow chamber assay. The rectangular cutout in the gasket defined the flow 
channel and the gasket thickness dictated the channel height.  Flow experiment setup was 
as described in [7] with minor modifications. Briefly, the flow channel was rinsed with 
DPBS+ prior to the start of flow adhesion experiments to clear cell surface debris and air 
bubbles in the channel. Ligand-coated spheres of a given size suspended in buffer/blood 
at fixed concentration 5 x 105 spheres/mL (unless otherwise noted) were introduced into 
the flow channel from an inlet reservoir via a programmable syringe pump (KD 
Scientific, model no. 780212, Holliston, MA). Flow adhesion assays were observed on a 
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Nikon TE 2000-S inverted microscope fitted with a digital camera (Photometrics 
CoolSNAP EZ with a Sony CCD sensor). Digital recording of experiments was via 
Metamorph analysis software.  
For experiments exploring particle adhesion to the cell monolayer against gravity, 
the flow chamber was inverted such that the HUVEC monolayer made up the top plate of 
PPFC and the particle adhesion occurred at the upper surface. Particles interacting with 
the cell monolayer were observed at a given instance (with continued flow) by careful 
flipping of the chamber back to the upright position.  For vertical flow adhesion assays, 
the flow chamber was oriented vertically with flow and particles were allowed to adhere 
to the lateral surface.  All adhesion experiments were conducted at 37oC and each cell 
monolayer was used once (i.e. only one experimental run per monolayer).  Unless 
otherwise noted, particles in flow were exposed to the monolayer surface for 5 mins. 
Since HUVEC used were pooled over multiple donors, variation in adhesion molecule 
expression between batches is expected to be minimum. 
2.7.1 Laminar Flow Assays 
For all flow experiments, wall shear rate (γw (s-1); WSR) within the flow channel 
was controlled via the adjustment of volumetric flow rate (Q) according to  
! 
"w =
6Q
h
2
w
;s
#1
(1)
 
 where Q is the volumetric flow rate (mL/min), h is the channel height (254 µm, unless 
otherwise noted)  and w is the channel width (1 cm unless otherwise noted). The wall 
shear stress (τw - dynes/cm2) can be calculated by multiplying the WSR by blood 
viscosity (µ), which is a function of temperature, Q, and blood hematocrit.  
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2.7.2 Pulsatile Flow Assays 
A programmable syringe pump was used to induce pulsatile flow in the horizontal 
PPFC.  Pulsatile flow assays utilized two flow profiles (Fig. 2.1). In profile I, blood was 
pulsed about 0 s-1 with a net flow in the forward direction.  Specifically, the syringe pump 
was set to run continuous loops of 14 s forward flow followed by 7 s backward flow for 
15 mins with maximum Q set at 1.29 mL/min (200 s-1), 3.225 mL/min (500 s-1) and 6.45 
mL/min (1000 s-1) for experiments with aVCAM-, aICAM- and sLeA-spheres, 
respectively. HUVEC monolayers were exposed to particles in pulsatile flow for 15 min.  
This flow time was chosen to ensure the same volume of particles pass through the 
chamber as in laminar experiments (5 mins of flow) since net forward flow with the 
pulsatile setting above occurs in one-third of the total cycle time (7 out of 21 s). In 
pulsatile profile II, flow was pulsed solely in the forward direction at ~3.1 mL/min (480 
s-1) for a total of 5 mins with the minimum and maximum forward flow rates set at 0.774 
mL/min (120 s-1) for 4 s and 7.74 mL/min (1200 s-1) for 2 s with no period of pause. 
Pulsatility in the flow channel was confirmed via visual analysis of video record of 
experiments and tracking of instantaneous volumetric flow rate Q(t), as shown in Fig. 
2.1. 
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Figure 2.1 Velocity profiles of pulsatile flow 
Flow profile (I) pulsing between 1000 s-1 and -1000 s-1 of WSR with a net 
forward flow and flow profile (II) pulsing about 480 s-1 of WSR (maximum 
and minimum WSR = 1200 s-1 and 120 s-1). 
 
2.7.3 Recirculating Flow Assays 
Recirculating flow assays employed a vertical-step flow channel (VSFC) [8] (Fig. 
2.2) with entrance and main channel heights of 127 µm and 508 µm (0.5 cm width), 
respectively. The step height was defined via layering of two gaskets – a half-length 
channel (custom cut) placed directly on ECs and a full-length channel placed on top of 
the first gasket. The sudden expansion at the step creates a recirculating flow (region 1 –
Fig. 2.2) where a two-dimensional flow with a parallel (Vx) and a normal flow velocity 
(Vz) with respect to the channel bottom wall is established. The recirculation vortex 
extends from the step to a reattachment point (region 2) where flow parallel to the wall is 
stagnant (i.e. Vx = 0) and only Vz is present.  Beyond the reattachment, flow moves 
forward, and a laminar profile is reestablished at far downstream (region 3). Laminar 
flow adhesion in the VSFC was analyzed at 200 and 500 s-1 of WSR in the main 
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chamber, while pulsatile flow experiments were conducted with profile II, for a total of 5 
mins. 
 
Figure 2.2 A schematic of a vertical step flow channel 
2.8 Data Analysis 
Particle binding density (#/mm2) is obtained by manually counting the number of 
particles bound on the cell monolayer every minute (for rate of attachment data) or after 5 
or 15 mins of flow (for particle binding data) and dividing this number by the area of the 
field of view (20x magnification, A = 0.152 mm2, unless otherwise stated). To account 
for potential variation in fluxes along the chamber length, data was collected at a constant 
position along the length of the chamber for all experiments. Particles were considered 
firmly adherent if they remained stationary for > 10 s. Each data point shown in graphs 
represents an average over at least three experiments and includes at least ten fields of 
view per experiment. Standard error bars were plotted. In some analysis, particle 
adhesion was normalized, i.e. the number of particles bound at 5 mins per area was 
divided by the total number of particles that entered the chamber based on particle 
concentration in blood, volumetric flow rate through the channel and flow time. For 
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recirculating flow experiments, the number of particles bound downstream of the step 
channel was counted in 100 µm intervals (area of strip = 0.034 mm2) – e.g. data reported 
for 200 µm represents particles bound between the 100 and 200 µm distant from the 
expansion step. For adhesion at far downstream where laminar flow is re-established, the 
adherent particles were counted at the 5000 µm distance from step [9]. Each data point 
represents an average over at least three experiments and includes at least five fields of 
view per experiment. Differences in adhesion levels were analyzed using a student t test, 
one-way ANOVA with Tukey post-test and two-way ANOVA with Bonferroni post-test.  
A value of p < 0.05 or p < 0.01 (in Chapter 5) was considered statistically significant, 
otherwise stated.   
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CHAPTER 3  
 
POTENTIAL ROLE OF SIZE AND HEMODYNAMICS IN 
THE EFFICACY OF VASCULAR-TARGETED 
SPHERICAL DRUG CARRIER  
 
 
ABSTRACT 
 
Targeting drug carriers to the vascular wall is of interest for localized delivery of 
therapeutics in many human diseases. Nanometer-sized spherical particles are widely 
proposed for use as carriers for vascular targeting, yet very little evidence has been 
presented as to their ability to interact with the vascular wall. Thus, this work focuses on 
elucidating the effect of particle size along with hemodynamics, blood rheology, and 
vessel size on the adhesion efficiency of targeted polymeric spheres to inflamed 
endothelium from laminar blood flow in vitro via parallel plate flow chamber assay 
(PPFC). My results shows that the binding efficiency of spheres to the endothelium from 
blood flow generally increased with increasing particle size, wall shear rate and channel 
height for particle sizes from 100 nm up to 10 µm. Nano-sized particles showed minimal 
adhesion to the endothelium from blood flow in horizontal (gravity and anti-gravity 
direction) and vertical channels on the order of small to medium-sized venules and 
arteries when compared to micron-sized spheres. Overall, the presented data suggest that 
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spheres 2 µm to 5 µm are optimal for targeting the wall in medium to large vessels 
relevant in several cardiovascular diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents of this chapter have been published as Charoenphol P, Huang RB and Eniola-Adefeso O. 
Potential role of size and hemodynamics in the efficacy of vascular-targeted spherical drug carrier. 
Biomaterials. 2010;31(6):1392-1402.  
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3.1 Introduction 
In recent years, vascular targeting has been explored for localized delivery of 
therapeutics in cancer [1, 2] as well as in pulmonary and cardiovascular diseases [3-5].  
However, existing literature have focused on identifying suitable endothelial cell targets 
(surface-expressed proteins), targeting molecules (e.g. antibodies/peptides) or 
characterizing the drug release properties of delivery vehicles. While biological cues and 
cellular processes are important in the endothelial response in human diseases, the 
characteristic forces ascribed to blood flow dynamics (hemodynamics) are a crucial part 
of understanding this process and its involvement in the pathogenesis of these diseases.  
Similarly, hemodynamics is important in the adhesive interactions of leukocytes (white 
blood cells) with the endothelium – a hallmark of the natural immune response. As such, 
hemodynamics must be an important consideration in the design of vascular-targeted 
drug carriers (VTDC) – yet has been absent in existing literature. To date, little emphasis 
has been placed on how physical characteristics, such as shape and size, along with 
hemodynamics will prescribe the ability of VTDC to marginate (localize and adhere) to 
the vessel wall.   
Due to their ease of fabrication and well-defined model for hydrodynamic 
interactions, spherical particles have been widely studied for targeting therapeutics to the 
vascular wall [6-8]. Particles size in the submicron down to tens of nanometer range are 
particularly attractive for intravenous delivery since they can pass through the 
microcirculation with ease [8] and are less vulnerable to immune clearance [6, 9]. 
However, in addition to their ability to navigate the circulatory network, VTDC must (1) 
possess the ability to find and bind the vessel wall from blood stream and (2) remain 
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bound long enough to release drug cargo or be internalized by the endothelial cells – 
these two constraints constitute the binding efficiency of targeted carriers. To date, very 
limited work exists in the literature evaluating the role of size on the eventual binding 
efficiency of spherical carriers to the vascular wall.  In one work, Decuzzi and co-
workers using a theoretical model for particle margination from the blood stream 
suggested that there is a critical radius (Rcritical ~ 50  - 250 nm, depending on particle 
density) for spheres at which their localization time to the wall from blood flow is 
maximum, and that VTDC with size larger (or smaller) than Rcritical would have a higher 
propensity for the vessel wall [10]. Their model accounted for a higher concentration of 
nano-sized spheres near the wall than micron-sized spheres based on the assumption that 
nanospheres can be injected into the blood stream at a higher concentration than 
microspheres. In addition, this model only focused on particle margination from close 
proximity to the wall and thus did not fully address the ability of targeted particles to 
navigate through the dense population of blood cells to reach the wall.  To date, no 
evidence has been put forth in the literature to suggest that nanospheres will navigate 
through blood similar to or better than microspheres; thus, a higher injection 
concentration for nanospheres may not necessarily translate to a higher concentration at 
the vessel wall.  Existing experimental works evaluating the effect of size/volume on the 
margination of spherical particles from mid-stream to the wall for potential vascular-
targeting applications via parallel plate flow chamber (PPFC) assays only studied these 
interactions in buffer [11, 12]. Thus, it is not clear if predictions made from such works 
would hold in blood flow.   
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Blood rheology is a known important factor in the interaction of leukocytes with 
the endothelium in vivo.  Specifically, the physical properties of erythrocytes or red blood 
cells (shape, size and deformability) allow them to be preferentially positioned in the 
centerline of blood flow forcing other blood cells (leukocytes and platelets) into a red 
blood cell (RBC)-free plasma layer (CFL) located towards the vessel wall thereby 
increasing the probability of leukocyte-endothelium interaction [13, 14].  While particle 
size and hemodynamics may be irrelevant in the microcirculation, these parameters will 
likely prescribe the binding efficiency of spherical carriers in medium to large blood 
vessels that are often associated with several chronic inflammatory and cardiovascular 
diseases (e.g. atherosclerosis) [15, 16].  Indeed, investigators have shown increased 
binding of vascular-targeted 10 µm spherical particles to cultured endothelium (~170%) 
when a physiological amount of RBCs is added to the flow medium similar to the 
previously described RBC-effect on neutrophils [17].  It is not clear, however, if these 
observed RBC-effect (enhanced margination) would also exist for the adhesion of smaller 
size spheres. Though a few studies of the localization (only – no adhesive interactions) of 
small spheres to the wall from blood flow existed have suggested that particles larger 
than 2 µm (up to 5 µm) can disproportionately accumulate (near wall excess) to the wall, 
it is not clear how accumulation will translate to particle adhesion to the wall in blood 
flow [18, 19]. Thus, the work presented herein aims to elucidate the potential role of 
hemodynamics and size in prescribing the binding efficiency of VTDC in flow 
mimicking physiological conditions in vivo via PPFC. Specifically, spherical particles 
conjugated with sialyl-Lewis A (sLeA), a ligand specific to the endothelial-expressed 
selectins, and with diameters ranging from 100 nm up to 10 µm were evaluated in a 
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PPFC for their ability to effectively bind to activated endothelial cells (aECs) from blood 
flow.  
3.2 Results 
The experimental set up used in this chapter is described in detail in Chapter 2. 
 
 
3.2.1 Sialyl Lewis A-coated spheres specifically adhere to activated HUVEC 
monolayer from flow in a PPFC 
Spheres with 10 µm diameter were used to confirm the specificity of sLeA to 
activated ECs (aECs). Overall, these spheres coated with sLeA were easily captured to the 
surface of IL1-β-activated endothelial cells from flow in the presence or absence of RBCs 
in a PPFC as shown in Fig. 3.1. As reported by others, the presence of RBCs enhanced 
the adhesion of particles to the EC surface [8] over particles in buffer (DPBS+) and 
plasma flow with no RBCs. The level of particle adhesion in plasma without RBCs was 
significantly lower than adhesion in buffer with no RBCs due to the viscosity of plasma 
being 1.5-fold higher than that of buffer (i.e. a higher viscosity translates to a higher wall 
shear stress that negatively affects particle adhesion in flow).  However, there was no 
significant difference in the adhesion of particles with RBCs in plasma compared ones 
with RBCs in buffer (not shown) at this WSR. Control experiments with sLeA spheres 
flowing over non-activated ECs, avidin-coated spheres over aECs, or sLeA spheres over 
aECs in the presence of EDTA (i.e. removal of divalent ions necessary for sLeA -selectin 
interactions) all showed no particle adhesion, thus confirming the specificity of the 
interaction between spheres and aECs.   
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Figure 3.1 Adhesion of sLeA- or avidin-coated 10 µm spheres from flow to EC 
monolayer in a parallel plate flow chamber and in the presence or absence 
of red blood cells (RBCs). WSR in the chamber = 200 s-1. 
n ≥ 3 and # = p < 0.01 compare to sLeA particles on IL1-β-activated 
endothelial cells.   
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3.2.2 Effect of size on particle adhesion to HUVEC from flow 
   sLeA -coated spheres sized from 100 nm to 10 µm were allowed to interact with 
aECs in a reconstituted blood flow (RBCs in homologous plasma with no leukocytes or 
platelets) at 30% hematocrit and with the WSR and channel height set at intermediate 
values of 200 s-1 and 254 µm.  The 200 s-1 WSR is a representative of flow in post 
capillary venules and the 254 µm height is in line with diameters of arterioles and venules 
in humans [20, 21]. The sLeA site density on spheres was adjusted to ~800 sites/µm2 via 
flow cytometry. For flow experiments, the particle concentration was held constant at 
5x105 particles per mL of blood for all particle sizes. It was found that the level of 
particle adhesion (per unit area at 5-min) on aECs at the above conditions decreased 
when the particle diameter (size) decreased from 10 µm to 0.1 µm as shown in Fig. 3.2A. 
Minimal amount of binding occurred for particles smaller than 2 µm in size. For all 
experiments (the range of WSR studied), spheres at ≥ 800 sLeA sites/µm2 displayed only 
firm adhesion to the cell monolayer. When the particle concentration was increased to 1 
and 5 x 106 particles/mL of blood at fixed %Hct, the level of particle binding increased 
proportionally without affecting the adhesion trend seen with particle size (data not 
shown).  Since for many drug delivery applications, carrier payload (i.e. volume) is of the 
utmost important [22], I conducted some experiments at a fixed volume concentration of 
2.44 x107 µm3 per mL of blood for all particle sizes (i.e. 5x104 particles/mL for 10 µm 
versus 3.5x108 particles/mL for 0.5 µm). Similar to experiments at fixed number 
concentration, particle volume adhesion increased with an increase in particle size up to 
10 µm as shown in Fig. 3.2B. 
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Figure 3.2 Adhesion of sLeA-coated spheres from blood flow to aEC monolayer in a 
PPFC at (A, C) a fixed number concentration of 5x105 particle/mL blood and 
(B, D) a fixed volume concentration of 2.44 x107 µm3/mL blood for all 
particle sizes (n ≥ 3).  
Channel height = 254 µm. Wall shear rate = 200 s-1. D is particle diameter 
(µm ) and *ns = not significantly difference.  
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The particle binding (Fig. 3.2A) and volume flux (Fig. 3.2B) replotted with particle size 
on a linear scale at the x-axis showed that the adhesion of spheres at both fixed particle 
concentration and volume linearly increased with particle diameter (Fig. 3.2 C and 3.2 
D). Since the adhesion trend with fixed volume was the same as with fixed particle 
concentration, the rest of the studies reported herein were conducted with particle 
concentration fixed at 5 x 105/mL and 30% Hct to conserve material.  
 
3.2.3 Effect of wall shear rate (WSR) on particle adhesion is a function of particle 
size and the presence of RBCs in flow  
Previous studies of particles/cells in flow have shown that their adhesive behavior 
depends on the magnitude of WSR [23, 24]. Thus, I investigated the role of WSR on 
particle adhesion to aEC monolayer from blood flow in the horizontal flow chamber at 
WSRs ranging from 200 to 1500 s-1 – typical values of in vivo human blood flow [20, 
21]. These experiments were conducted at a fixed channel height of 254 µm. At 200 s-1, 
the level of particle adhesion increased with increasing particle size for most particles 
tested as shown in Fig. 3.3A. The adhesion of 0.1 µm particles was not significantly 
different from that of 0.5 µm at this WSR (data not shown). When the WSR was 
increased to 500 s-1, adhesion increased only when the particle size increased from 0.5 
µm up to 5 µm. The adhesion of 10 µm spheres at this shear rate was significantly lower 
than those measured for 2 and 5 µm particles. A further increase in WSR to 1000 and 
1500 s-1 resulted in adhesion, which only increasing with an increase in particle size from 
0.5 µm up to 2 µm. Further increases in size beyond 2 µm at these WSRs resulted in the 
same or significantly lower binding than displayed by 2 µm particles. Furthermore, 2 and 
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5 µm showed increase in adhesion levels with each step increases in WSR from 200 s-1 
up to a critical value (WSRcrit).  Beyond this WSRcrit, adhesion levels decreased with an 
increase in WSR. While 10 µm spheres appear to not have a critical WSR for adhesion 
between 200 and 1500 s-1, a reduction in WSR to 100 s-1 resulted in the appearance of a 
WSRcrit for these particles at 200 s-1 (Fig 3.3A-insert). On the contrary, the apparent 
WSRcrit displayed by 0.5 µm was found to not be significant via two-way ANOVA.  
Again, 0.1 µm spheres displayed minimal adhesion at all WSRs (not shown). Overall, the 
magnitude of the WSRcrit for a given particle was a function of its size.  
To determine if the significant drop in particle binding beyond WSRcrit is due to a 
deficiency in particle delivery to the surface (i.e. ability of particle to localize through 
RBCs to the wall) or higher hemodynamic forces disrupting receptor-ligand 
interactions/increasing particle detachment, experiments were conducted at 500 s-1 with 
10 µm particles having a significantly higher surface sLeA density than the 800 sites/µm2 
used for the data displayed in Fig. 3.3A.  At a WSR of 500 s-1 and 254 µm channel 
height, a 2.5-fold increase in sLeA site density for 10 µm particles (from 800 to 2000 
sites/µm2) resulted in equivalent increase in particle binding as shown in Fig. 3.3B.  A 
similar or higher (up to 5000 site/µm2) fold increase in sLeA site did not yield a 
significant change in the level of binding for 2 (not shown) or 5 µm particles at 500 s-1 – 
a WSR which is less than the WSRcrit for these particles. Thus, it can be concluded that 
the significant drop in adhesion beyond WSRcrit is due to higher disruptive hemodynamic 
forces interfering with particle adhesion rather than ineffective particle localization to the 
wall.   
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Figure 3.3 (A) Adhesion of sLeA spheres (~800 sites/µm2) as a function of wall shear rate 
in the chamber. (B) Adhesion of 5 and 10 µm spheres as a function of sLeA 
site density at 500 s-1. (C) Binding flux of 5 µm spheres at different shear rates 
normalized to the total number of particles introduced into the chamber at 
each shear rate.  
Particle concentration fixed at 5x105 particles/mL blood. Channel height = 
254 µm. n ≥ 3 and # = p < 0.01 compare to binding at 200 s-1. *ns = not 
significant.   
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To better understand the increase in particle adhesion with increase in WSR in the 
range that is less than the WSRcrit, the data in Fig. 3.3A was normalized to the total 
number of particles introduced into the flow chamber at each WSR. Normalized particle 
adhesion remain the same or decreased as the shear rate increased from 200 to 1500 s-1 as 
shown in Fig. 3.3C.  A similar trend was seen when a constant flux of particles (6.45x105 
particles/mL) was introduced over aEC at all WSR, i.e. particle concentration was 
5x105/mL at 200 s-1 versus 1x105/mL at 1000 s-1 (data not shown). When particle 
adhesion occurred in saline buffer, i.e. no RBCs, an opposite adhesion trend was 
observed.  Particle adhesion decreased (or remained the same for particle smaller than or 
equal to 2 µm, displaying minimal adhesion) as the WSR increased from 100 s-1 to 640 s-
1 as shown in Fig. 3.4. 
 
3.2.4 Effect of channel height on particle adhesion  
To determine whether the trends observed with WSR and particle size are 
generally applicable, I varied the channel height between 127, 254, 508 and 762 µm – a 
range representative of arterioles and venules.  Adhesion at all channel heights was 
observed at 200 s-1 by adjustment of the channel flow rate according to equation 1 (in 
Chapter 2) (e.g. Q254µm = 4Q127µm).   For 127 and 254 µm channel heights, adhesion 
increased with an increase in particle size up to 10 µm as shown in Fig. 3.5A. At 508 and 
762 µm heights, adhesion only significantly increased as size increased from 0.5 to 5 µm. 
However, the magnitude of adhesion at a fixed particle size significantly increased as the 
channel height increased from 127 to 762 µm for all particle size larger than 0.5 µm.   
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Figure 3.4 Adhesion of sLeA spheres in saline (DPBS+) buffer (no RBCs) to aEC 
monolayer as a function of wall shear rate in a horizontal PPFC.  
Particle concentration fixed at 1x106/mL of buffer. Channel height = 254 µm. 
n ≥ 3.    
  48 
 
 
 
 
 
 
 
Figure 3.5 Adhesion of sLeA spheres as a function of channel height. (A) Wall shear rate 
= 200 s-1, (B) Wall shear rate = 500 s-1.  (C) Binding of spheres at different 
channel heights normalized to the total number of particles introduced into the 
chamber at each channel height.  
Particle concentration fixed at 5x105 particles/mL blood. n ≥ 3. *ns = not 
significant and ** = not significant compared to immediate smaller particle 
size at fixed channel height.   
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Overall, 0.1 (not shown) and 0.5 µm spheres showed minimal levels of adhesion at most 
channel heights: there was no significant difference in adhesion levels seen at the 
different heights tested.  Data reported in the previous section suggested that particle 
adhesion in blood flow was strongly dependent on the magnitude of WSR in the 
chamber.  Thus, it is likely that the trend in adhesion with changing channel height is 
coupled to the magnitude of the fixed WSR.  To verify this, adhesion of 5 and 10 µm 
particles (sizes most vulnerable to WSR) at various channel height was observed at 500 s-
1.  The data presented in Fig 3.5B, showed a reversal in adhesion trend seen for 10 µm 
particles as the channel height increased.  While adhesion trend remained the same for 5 
µm particles at 500 s-1, the magnitude of increase in adhesion with an increase in channel 
height at this WSR was smaller than seen at 200 s-1. To better understand the increase in 
particle adhesion with increase in channel height, the data in Fig. 3.5A was normalized to 
the total number of particles introduced into the flow chamber at each channel height. 
Normalized particle adhesion remain the same or decreased as the channel height 
increased from 127 to 762 µm as shown in Fig. 3.5C Again, when adhesion assays were 
conducted with particles in saline buffer, adhesion was either the same or lower for all 
particles as the channel height increased similar to the data in Fig. 3.4 (data not shown).  
 
3.2.5 Effect of gravity on particle adhesion 
Since adhesion in the horizontal chamber occurs in the direction of gravity, it is 
possible that the higher adhesion with larger particles is due to their larger weight (i.e. 
gravity).  Thus, experiments were conducted in inverted and vertical channels to assess 
the potential contribution of gravity to particle adhesion from blood flow.   Fig. 3.6A 
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shows adhesion levels as a function of particle size and channel height in an inverted 
chamber where particle interaction with aECs monolayer occurred against gravity. For 
this setup, minimal particle adhesion was seen at the 127 µm height for all particle sizes 
tested in blood.   A channel height increase to 254 µm resulted in a significant increase in 
binding for particles 2 µm or larger. A further increase in channel height to 508 µm 
similarly resulted in a significant increase in adhesion for these particles.  Overall, the 
adhesion at heights larger than 127 µm increased with increasing particle diameter (0.5 to 
10 µm).  When WSR in the inverted chamber was varied from 200 to 500 s-1 at a fixed 
channel height, particle binding to the aEC monolayer followed the same trend as seen in 
the upright chamber (i.e. adhesion in the direction of gravity), where higher adhesion 
levels were recorded at 500 s-1 when compared to that at 200 s-1 only for particles 5 ?m 
or smaller (Fig. 3.6B). Control experiments with particles in saline or plasma with no 
RBCs (Fig. 3.6A - insert) yielded no particle adhesion to the wall in the inverted chamber 
for all particle sizes and channel heights studied. Particle adhesion in the vertical chamber 
was also similar to that in upright and inverted chambers with adhesion increasing with 
an increase particle diameter at 254 µm channel height and 200 s-1 (Fig. 3.7).  Again, 
increasing the WSR within the chamber to 500 s-1 showed particle adhesion increasing 
with an increase in particle size up to 5 µm. There was also no significant difference in 
adhesion levels seen between adhesion in upward and downward flow for all particles 
tested in the vertical chamber (data not shown).  Overall, the magnitude of particle 
binding in the inverted or vertical chamber was mostly the same as that seen in the 
horizontal channel (Figs. 3.3 and 3.5).   A significant difference in binding was only seen 
with 5 and 10 ?m particles at low channel heights/WSRs in the inverted chamber.    
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Figure 3.6 Adhesion of sLeA-spheres from blood flow to aEC monolayer in an inverted 
PPFC (adhesion in the anti-gravity direction) as a function of (A) channel 
heights at 200 s-1 (B) shear rate at 254 µm channel height. Insert A  = 
Adhesion of sLeA-spheres in plasma with no red blood cells in an inverted 
PPFC at 254 µm channel height (control experiment). 
Particle concentration fixed at 5x105 particles/mL blood. n ≥ 3 and # = p < 
0.05 compare to adhesion in horizontal flow channel.   
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Figure 3.7 Adhesion of sLeA-spheres from blood flow to aEC monolayer as a function of 
wall shear rate in a vertically oriented PPFC with upward flow (adhesion in 
the lateral direction).  
Channel height = 254 µm. Particle concentration fixed at 5x105 particles/mL 
blood. n ≥ 3 and # = p < 0.05 compare to adhesion in horizontal flow channel.  
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3.3 Discussion 
Of the many physiological processes regulated by the endothelium, inflammation - 
a normal host response to tissue injury - is of particular interest for vascular targeting due 
to its known involvement in the pathogenesis of several human diseases, including 
atherosclerosis [25].  Selectins, ICAM-1 and VCAM-1 are the biological molecules 
primarily expressed by endothelial cells during inflammation to help recruit leukocytes to 
the vascular wall – a hallmark of inflammation response.  Many researchers have 
explored targeting therapeutics to the vascular wall in human diseases via inflammation 
and its endothelial-expressed leukocyte adhesion markers (LAMs); where polymeric 
microspheres conjugated with selectin counter-receptor or antibodies against LAMs show 
specific interaction with inflamed endothelium from flow both in vitro and in vivo [26-
28]. Most of these works, however, have focused on carrier characteristics or the 
specificity of targeting ligand.  Here, I explore the role of particle size and hemodynamics 
in the ability of targeted polymeric spheres to adhere to inflamed endothelium from 
physiological flow in vitro.  Specifically, polystyrene spheres of different sizes 
conjugated with sLeA, a carbohydrate ligand specific to the selectins, were allowed to 
interact with activated monolayer of human umbilical vein endothelial cells (HUVECs) 
from blood flow in a PPFC. Similar PPFC adhesion assays have been successfully used 
to elucidate the biophysics of leukocyte-endothelium interactions [29, 30], and sLeA was 
the molecule of choice for mediating particle adhesion due to its superior capacity for 
adhesive interaction with the selectins from high shear (fast on-rate) over most antibodies 
specific to LAMs [31, 32].    Overall, my results show that the efficiency of targeted 
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particles binding to HUVEC from flow in the presence of blood cells is a function of 
particle size, channel height and wall shear stress within the flow channel.   
 
Specifically, I found that the adhesion of sLeA-coated spheres increased as their 
diameter increased from 0.5 to 10 µm at 200 s-1.  Experiments conducted at fixed particle 
volume concentration in this WSR range resulted in particle volume adhesion levels 
increasing with an increase in particle diameter (Fig. 3.2B).  A conversion of volume 
adhesion data back to number binding followed by a normalization to the total number of 
particle fed suggested that particle margination efficiency also increased when particle 
size increased from 0.5 to 10 µm in this shear range.  While it is plausible that 
margination could be affected by particle concentration in itself (e.g. particle margination 
efficiency is higher at higher particle concentration), my experiments with particle 
concentrations between 1 x 105 and 5 x 106/mL showed that binding increased 
proportionally with particle concentration (data not shown). This adhesion trend seen at 
this intermediate WSR agrees with a previous report by Decuzzi et al., where the 
adhesion (volume and number) of spheres to the wall in low shear (~7.75 s-1) buffer flow 
increased as the particle diameter increased from 500 nm to 10 µm [12].  
 
As the WSR in my assays increased to high levels (500 – 1500 s-1), the increase in 
adhesion with an increase in particle size progressively excluded larger particles (Fig. 
3.3A).  This coupling effect of size and WSR on the adhesion of spherical particles has 
been previously reported by Goetz et al. [11] and can be explained by the interplay 
between three processes governing particle margination (delivery from midstream and 
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binding) to the wall: 1) transport of particle to the wall that is typically regulated by 
convection and diffusion, 2) reaction between particle ligands and cell surface-expressed 
receptor at the wall (or forward reaction rate) that is controlled in part by receptor/ligand 
density and particle slip velocity (i.e. particle translational velocity due to Q and adjusted 
for wall effect) [33], and 3) detachment of particles that is regulated by WSR and the 
reverse reaction rate [34].  At constant and adequate receptor and ligand densities, a 
higher slip velocity and/or a larger particle diameter negatively affects particle binding. 
Thus, when low WSRs (resulting from low Q) exist in the chamber, localization of 
particle to the wall dominates (i.e. transport-limited regime – TLR) and appears to favor 
larger particles (i.e. the slip velocity and disruptive forces that regulate adhesion and 
detachment are relatively low). Indeed, experiments with a 3- to 6-fold increase in sLeA 
site density on particles did not increase adhesion when in the transport-limited WSR 
range (e.g. binding of 5 µm particles with 800 and 2000 sLeA sites/µm2 at 500 s-1 – Fig. 
3.3B). At higher WSRs, particle adhesion occurs in a “reaction-limited” regime (RLR) 
where high slip velocities and disruptive forces exist and disproportionately affect larger-
sized particles [11] (i.e. larger particles display lower binding relative to smaller ones). 
Hence, increasing the sLeA site density on particle size equal to or larger than 2 µm 
translated to a significant increase in particle binding when in the RLR (e.g. Fig. 3.3B).   
 
This sort of “shear threshold” effect on particle binding is even more evident when 
exploring the effect of WSR on adhesion for a given particle size.   The presented data in 
Fig. 3.3A shows that particles size equal to or larger than 2 µm displayed increases in 
their binding with an increase in WSR up to a critical point. Beyond this critical point, 
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adhesion decreased with further increases in WSR. Overall, the magnitude of the critical 
WSR decreased as the particle size increased from 2 to 10 µm.  A statistical analysis of 
the adhesion data for nanospheres (two-way ANOVA) suggested that these particles did 
not display a critical WSR, i.e. particles smaller than 2 µm displayed minimal adhesion 
for all WSR.  While Goetz and co-workers previously defined a transport and reaction-
limited adhesion regimes for particles adhesion from buffer flow to reactive surfaces in a 
PPFC [11], they did not show an increase in particle adhesion with an increase in WSR 
for particles of similar sizes and WSR range (75  - 600 s-1) as studied here (i.e. no 
occurrence of critical WSR). The most notable differences between my study and one by 
Goetz and co-workers are in the type (and possibly density) of adhesion ligand used 
(PSGL-1 versus sLeA) and the absence of RBCs in their adhesion assays. Though 
differences in ligand type and/or density are plausible reasons for the differences in the 
observed trend for particle adhesion, I find that the existence of a critical shear for 
particle binding disappeared when adhesion occurred in saline buffer (absence of RBCs) 
at the same WSR range studied by Goetz and co-workers (Fig. 3.4).  Thus, it could be 
concluded that the shear threshold effect at a fixed particle diameter and the overall 
adhesion trend reported herein result from the presence of RBCs in flow.   Indeed, several 
investigators have reported that RBCs interaction with particles or cells in blood flow 
affect the adhesion of the latter to reactive surfaces both in vitro and in vivo, where 
enhanced particle/cell margination is seen in the presence of RBCs [14, 35, 36].  
However, many of these reports have focused on the effect of blood hematocrit levels and 
RBC aggregation on particle/cell binding.  Very limited works have evaluated the effect 
of shear on the magnitude of particle/cell margination to the vessel wall from blood flow.  
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In one work, Eckstein and co-workers reported that the localization of non-targeted 
spheres to the wall or “near wall excess (NWE)” in the presence of RBCs increased with 
an increase in WSR up to 400 s-1 in a 100 µm diameter channel and found that particles 
smaller than 2 µm did not show NWE at all conditions studied [19].  Their study, 
however, was done at a 15% Hct – hemorheology and the level of leukocyte margination 
changes with variation in blood hematocrit up to 30% Hct [35]. Jain and co-workers, 
however, reported that the efficiency of lymphocyte adhesion to the wall from blood flow 
(~30% Hct) decreased with an increase in WSR with no obvious evidence of lymphocyte 
NWE [37]. Similarly, adhesive dynamics simulation by Chang and Hammer showed a 
decrease in cell adhesion with increasing WSR; however, their study focused on a WSR 
range (1 - 12 s-1) much lower than studied herein [33]. 
 
Thus, the question remains: what is responsible for the shear threshold effect on 
particle binding? While it is likely that the shear threshold at fixed particle sizes seen 
herein is due to the biphasic response of reaction rate to WSR (i.e. force loading on 
receptor-ligand bond), shear threshold effect relating to receptor-ligand reaction rates for 
particle/cell adhesion in the presence or absence of RBCs have only been repeatedly 
shown for interactions involving L- and P-selectins [23, 24, 38, 39].   Particle adhesion to 
aEC as reported herein is via E-selectin, i.e. minimal expression of P-selectin occurs with 
IL-1β activation for 4-hr [40], and L-selectin is only found on leukocytes. Also, the fact 
that particle adhesion did not respond to increases in sLeA site density (improved reaction 
rate) in the TLR suggests that RBC-induced particle localization to the wall is not 
enhanced at higher WSR. Lipowsky and Pearson previously reported a similar 
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observation with leukocytes where little change in the in vivo margination of these cells 
was seen with increasing shear [36]. Instead, I suggest that the effect of particle binding 
with WSR at fixed particle sizes reported here is likely due to physical interactions 
between RBCs and targeted particles as previously suggested by Jain and co-workers 
[37]. Specifically, separate from the initial RBC-mediated localization of particles to the 
wall, RBC collision with particles in the plasma layer (RBC-free layer) produces a 
normal acting adhesive force that enhances particle collision with the wall and their 
subsequent adhesion.   Thus, when in the transport-limited adhesion regime, the excess 
RBC-generated force aids particles in overcoming the increasing slip velocity and 
disruptive forces resulting from increases in flow velocity and WSR, respectively. This, 
in turn, helps particles maintain the same binding efficiency with increasing WSR in this 
regime (e.g. adhesion efficiency of 5 µm spheres from 200 – 500 s-1; Fig. 3.3C).  The 
maintained adhesion efficiency then results in higher binding with higher WSR since a 
higher number of particles enter the flow chamber per time at higher WSRs.   In addition 
to their lack of NWE as previously suggested [19], it is likely that particles smaller than 2 
µm did not respond to increases in WSR due to their minimal physical interaction with 
RBCs since they are significantly smaller than the height of the plasma layer (~2 - 12 µm 
in height [14, 41]). 
 
Adhesion assays in horizontal chambers with varying channel height at a fixed 
WSR of 200 s-1 also showed particle fluxes increasing with increases in channel height 
from 127–762 µm for all particles greater than 2 µm. However, the normalization of 
particle binding to the number of particles passing over a fixed area showed that the 
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efficiency of particle binding decreased with most channel height increase for all particle 
sizes studied herein. This decrease in binding efficiency with an increase in channel 
height may in part be due to a higher particle slip velocity at fixed WSR as the channel 
increases. 
 
Adhesion assays in inverted and vertical chambers showed similar adhesion trends 
as seen with assays in horizontal channel for all particle sizes. This observation suggests 
minimal contribution of gravity to particle localization to the wall.  The lack of 
significance in the magnitude of particle adhesion to the wall observed in vertical and 
horizontal chambers reported herein agrees with a previous report by Abbitt and Nash 
[42]. While this observed similarity in particle (and cells) adhesion between these two 
chamber orientations may suggest gravity does not play a role in adhesion in horizontal 
channels, the significant decrease in adhesion observed for large particles (5 and 10 µm) 
in the inverted versus horizontal chamber may suggest otherwise. However, it is likely 
that the significant decrease in adhesion seen in inverted chambers is related to potential 
differences in the characteristics of the RBCs-free plasma layer between the top and 
bottom of the PPFC.  Reports in the literature have shown that the average plasma layer 
thickness can differ significantly between the top and bottom wall in a horizontally 
aligned channel or vessel in vivo [43, 44].   
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CHAPTER 4  
 
TARGETING THERAPEUTICS TO THE VASCULAR 
WALL IN ATHEROSCLEROSIS  
– CARRIER SIZE MATTERS  
 
 
 
ABSTRACT 
 
 
Vascular-targeted imaging and drug delivery systems are promising for the 
treatment of atherosclerosis due to the vast involvement of endothelium in the initiation 
and growth of plaque. Herein, I investigated the role of particle size in dictating the 
ability of vascular-targeted spherical particles to interact with the vascular wall from 
pulsatile and recirculating human blood flow relevant in atherosclerosis.  In vitro parallel 
plate flow chambers (PPFC) with straight or vertical step channel were used to examine 
the localization and binding efficiency of inflammation-targeted polymeric spheres sized 
from 0.2 to 5 µm to inflamed endothelium from disturbed reconstituted and whole blood 
flow. The efficiency of particle binding in disturbed reconstituted blood flow increases as 
spherical diameter increases from 500 nm to 5 µm. No significant difference was 
observed between adhesion of 200 nm and 500 nm spheres. Binding efficiency for all 
particle size was enhanced in disturbed whole blood flow except adhesion of 5 µm in 
pulsatile whole blood. The presented data shows that the binding efficiency of vascular-
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targeted drug carriers in blood flow is a function of particle size, wall shear rate, flow 
type, blood composition and ligand characteristics. Overall, the presented results suggest 
that micron-sized spherical particles (2 µm), not nanospheres, are optimal for vascular-
targeted drug delivery applications in medium to large vessel relevant in atherosclerosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents of this chapter have been published as Charoenphol P, Mocherla S, Bouis D, Namdee K, Pinsky 
DJ and Eniola-Adefeso O. Targeting Therapeutics to the Vascular Wall in Atherosclerosis – Carrier Size 
Matters. Atheroslcerosis. 2011;217(2):364-370.  
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4.1 Introduction 
Atherosclerosis is the major cause of coronary artery disease – the leading cause 
of mortality in the US [1].  Current treatments for atherosclerosis include oral statins 
aimed at reducing high cholesterol (LDL) levels and surgical interventions such as 
balloon angioplasty and stent placement. However, acute coronary events can still occur 
in patients who have undergone aggressive statin therapy [2], and surgical intervention 
does not address the underlying cause of the disease and thus cannot prevent 
reoccurrence of stenosis. Consequently, targeted imaging and drug delivery systems have 
gained interest as a means to improve current therapies [3]. Imaging modalities for 
atherosclerosis are typically focused on noninvasive detection of the disease state, which 
can allow for better understanding of disease pathology and thus offer opportunities for 
more effective treatments.  Similarly, targeted drug delivery can offer a high drug 
efficacy at target site while minimizing side effects often associated with systemic 
delivery. Overall, previous works exploring imaging and drug targeting in atherosclerosis 
have focused on targeting vascular wall (VW) expressed molecules associated with 
plaque rupture, such as fibrin [4, 5], and inflammation (e.g. selectins, ICAM-1 and 
VCAM-1) [6-8].  Regardless of the adhesion moiety targeted, the overall efficacy of 
vascular-targeted therapies depends on the ability of carriers to marginate (localize and 
adhere) to the VW in sufficient density similar to the margination of white blood cells [9] 
prescribed by hemorheology and hemodynamics [10].  
Limited works in the literature have focused on the ability of targeted 
nanospheres, commonly proposed carriers, to interact with the VW in disturbed flow – an 
important consideration for the design of effective vascular-targeted therapy for 
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atherosclerosis which preferentially affects arteries in areas with high disturbance in 
blood flow (e.g. where low average wall shear, pulsatility and blood recirculation co-
exist) [11].   Existing studies of vascular-targeted carriers have investigated binding 
dynamics only in laminar buffer flow [12] and most have focused on microspheres only 
[13, 14]. Published in vivo works of nanospheres targeting the VW have mostly focused 
on capillary beds/post-capillary venules where the role of hemorheology is likely 
minimal [15].  Works describing nanospheres binding to the wall in large vessels [6, 16] 
have either been with spheres injected directly to the wall and/or have not evaluated 
binding as a function of particle size.  I recently reported that the binding efficiency of 
vascular-targeted spheres in laminar blood flow directly correlated with their size [17, 
18]; however, this trend may not necessarily extend to particle dynamics in disturbed 
blood flow relevant in atherosclerosis. Here, I present data for the binding dynamics of 
inflammation-targeted polystyrene (PS) spheres of nanometer to micrometer size to the 
endothelium in disturbed blood flow via in vitro assays with human blood. 
4.2 Results 
The experimental set up used in this chapter is described in detail in Chapter 2.  
4.2.1 Adhesion of spheres in pulsatile flow 
Sialyl-LeA, aICAM, and aVCAM-coated spheres suspended in reconstituted blood 
specifically bind to activated endothelial cell (aEC) monolayers from pulsatile flow. Fig. 
4.1A shows that the level of sLeA-sphere adhesion increased with increasing spherical  
diameter from 0.5 to 5 µm for pulsatile profiles I and II. No significant difference was 
observed between adhesion of 200 nm and 500 nm spheres.  Overall, sLeA-nanosphere 
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adhesion was ~ 4-11 and ~ 4-13 fold lower than that of microsphere adhesion in pulsatile 
profile I and II, respectively.  Normalization of binding by the total number of particles 
introduced into the PPFC indicated that there was no significant difference in particle 
binding between the two pulsatile profiles (data not shown). Both types of pulsatile flow 
improved particle adhesion for all sizes compared to binding in laminar flow at the same 
peak shear rates and at a fixed total number of particles as shown in Fig. 4.1B (i.e. 15 
mins of pulsatile profile I flow compared to 5 mins of laminar flow at 1000 s-1, and 5 
mins of profile II flow compared to 2 mins of laminar flow at 1200 s-1 – fixed blood 
volume).  Only firm adhesion (no rolling) was observed for all sLeA-coated spheres at the 
site density used. 
Antibody coated spheres did not adhere in profile I flow with peak WSR at 1000 
s-1 (not shown).  At 500 s-1 of peak WSR, aICAM-spheres displayed similar adhesion 
trend to the ones observed with sLeA-spheres (Fig. 4.1C), i.e. aICAM-nanospheres 
displayed 5-10 fold lower adhesion than microspheres.  Also, adhesion in pulsatile flow 
was enhanced ~2 fold for 0.5-2 µm aICAM-spheres and 50 fold for the 5 µm spheres 
compared to adhesion in laminar flow at 500 s-1 (data not shown).   The binding of 
aVCAM-coated spheres was minimal at 500 s-1 of peak WSR.  At 200 s-1, 500 nm 
aVCAM-spheres had a 3.4 fold lower binding density at the wall than aVCAM 
microspheres.  There was no significant difference in binding densities between 2 and 5 
µm aVCAM-spheres (Fig. 4.1D).  
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Figure 4.1 (A) sLeA-spheres binding in pulsatile reconstituted blood flow (open bar = 
profile I at peak WSR = 1000 s-1 and shaded bar = profile II). (B) Ratio of 
sLeA-spheres adhesion in pulsatile flow to adhesion in laminar flow at peak 
shear rates (1000 s-1 for profile I and 1200 s-1 for profile II). (C) anti-ICAM-1 
and (D) anti-VCAM-1 coated spheres binding in pulsatile reconstituted blood 
flow (profile I) with peak WSR at 500 s-1 and 200 s-1, respectively.  
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4.2.2 Adhesion of spheres in recirculating flow 
Particle binding in recirculating reconstituted blood was observed in the VSFC.   
At 200 s-1, the adhesion of 2 and 5 µm spheres increased with distance from the step up to 
just beyond the reattachment point (observed at 170 µm from step – see Chapter 2) and 
then decreased along the channel length to far downstream (Fig. 4.2A).  No obvious peak 
in adhesion was observed for nanospheres. The ratio of peak adhesion for microspheres 
to their adhesion levels at far downstream appears to directly correlate with size.   
Specifically, the “peak to far downstream” adhesion ratio was 2.4 and 3.6 for 2 and 5 µm 
spheres, respectively.  There was no significant difference in the “peak to far 
downstream” ratios between 200 and 500 nm spheres (1.5 and 1.2 respectively) but these 
ratios were significantly lower than observed with microspheres.  Furthermore, the 
adhesion of all sLeA spheres at the far downstream region (laminar flow regime [19]) was 
significantly higher compared with the adhesion of the same particles in laminar flow in 
channels with no step at the same height and WSR (see Fig. 6A in [18]).  Overall, 
nanosphere adhesion at 200 s-1 was 6-20 fold lower than that of microspheres at peak 
adhesion and 3-6 fold lower at far downstream.  A similar trend was observed for particle 
adhesion in VSFC at 500 s-1 as shown in Fig. 4.2B.  Microsphere adhesion peaked 
between 400 and 500 µm (reattachment point at 400 µm from step), and the adhesion of 
nanospheres was ~15-25 fold lower than that of microspheres at peak adhesion.     Only 
firm adhesion was observed for all sLeA-spheres in the VSFC.  
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Figure 4.2 sLeA-coated spheres binding in the VSFC with reconstituted blood flow.  Far 
downstream conditions is (A) 200 s-1 of laminar shear, (B) 500 s-1 of laminar 
shear, and (C) pulsatile profile II (average WSR = 480 s-1).  Dash line 
represents observed reattachment point.  
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4.2.3 Adhesion of spheres in combined pulsatile and recirculating flow 
Microspheres did not show any obvious peak in their adhesion in pulsatile 
reconstituted blood flow in the VSFC (Fig. 4.2C) likely due to the fluctuation of the 
reattachment point with changes in WSR of the pulsing flow.  Nanosphere adhesion was 
~7-21 fold lower at peak adhesion relative to microsphere adhesion with pulsatile flow in 
the step channel. When compared to adhesion under laminar flow in the same VSFC and 
average WSR of ~500 s-1 (Fig. 4.2B), pulsatility did not enhance microsphere adhesion in 
the recirculation region (Fig. 4.2C).  Far downstream adhesion in the VSFC was 
significantly different between pulsatile (Fig. 4.2C) and laminar flow (Fig. 4.2B) only for 
5 µm spheres.   
 
4.2.4 Adhesion of spheres in whole blood flow 
As in reconstituted blood experiments, sLeA microspheres displayed higher 
binding than nanospheres in pulsatile (profile I) whole blood flow (~45% Hct; Fig. 4.3A). 
However, 2 µm spheres showed significantly higher adhesion than 5 µm spheres. 
Overall, the adhesion of 0.2, 0.5 and 2 µm sLeA spheres in pulsatile whole blood flow 
was significantly higher (~2–4 fold) than levels observed in reconstituted blood at 30% 
Hct (Fig. 4.1A). No difference in adhesion was observed for 5 µm sLeA spheres between 
whole and reconstituted pulsatile blood flow.  The amount of white blood cells (WBCs) 
bound to ECs along with spheres was statistically the same (~2500 site/µm2) for all 
particle sizes (data not shown).   
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Figure 4.3 sLeA-coated spheres binding in whole blood. (A) Pulsatile (profile I) flow in 
the straight channel PPFC and (B) steady flow at 200 s-1 (main chamber) in 
the VSFC. * = Significant increase in particle binding relative to adhesion in 
pulsatile (profile I) reconstituted blood flow for particles of the same sizes.  
Dash line represents observed reattachment point.  
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Microspheres still displayed significantly higher adhesion than nanospheres for whole 
blood experiments in the VSFC at 200 s-1 (Fig. 4.3B). However, unlike pulsatile whole 
blood flow, 5 µm sLeA-spheresdisplayed ~2 fold higher adhesion than 2 µm spheres in 
the recirculation/reattachment region.  The difference in adhesion between 2 and 5 µm 
spheres was not significant at far downstream.  Furthermore, all sphere sizes showed 
higher levels of adhesion when compared to adhesion levels in similar experiments using 
reconstituted blood (Fig. 4.2A).  The gain in whole blood adhesion density for VSFC 
experiments was the highest for 2 µm spheres (~4 fold compared to 2-3 fold for 0.5 and 5 
µm spheres) in all three regions. The adhesion of WBCs was again the same for all 
particle sizes in all regions of the VSFC (data not shown). 
 
4.3 Discussion 
Targeting particles to the vascular wall for drug delivery and/or imaging is of 
great interest in the treatment of atherosclerosis.  Here, I investigated the role of particle 
size in dictating the ability of polymeric spheres to localize and adhere to inflamed 
endothelium in physiological flow conditions relevant to atherosclerosis. E-selectin, 
ICAM-1 and VCAM-1 are known to be overexpressed by endothelial cells (ECs) in 
atherosclerosis [20]. Others also showed that in vivo selectivity to ECs over plaque in 
mice was greatest when VCAM-1 and selectin were targeted [21, 22].  Thus, I evaluated 
the binding of 200 nm to 5 µm sLeA-, anti-ICAM-1 (aICAM), or anti-VCAM-1 
(aVCAM) coated polystyrene spheres to activated ECs (aECs) from human reconstituted 
or whole blood flow in vitro with channels of various. Overall, my results showed that 
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the binding efficiency of vascular-targeted spheres in blood flow is a function of particle 
size, wall shear rate, flow type, blood composition and ligand characteristics.     
Specifically, the adhesion of sLeA-spheres in pulsatile reconstituted blood flow 
pulsing about a zero shear (profiles I) or between low and high shear (profile II) 
increased with particle diameter (from 0.5 to 5 µm; Fig. 4.1A).  This suggests that 
particle margination efficiency increased with increasing spherical diameter since 
experiments were conducted at a fixed particle flow concentration. The 2-3 fold 
enhancement of particle adhesion with pulsatile flow in the straight channel PPFC (Fig. 
4.1B) directly correlates with the increase in the residence time of particles in the PPFC 
with pulsatile flow relative to laminar flow, suggesting that increased residence time is 
likely the major factor contributing to adhesion increase under pulsatile flow.  The 6-fold 
increase in the adhesion of 5 µm spheres in profile II flow relative to their adhesion under 
laminar flow at the peak WSR of 1200 s-1 is likely due to the adhesion limitations faced 
at this WSR with the sLeA site density used. I previously showed that at 1200 s-1 of 
laminar shear and ~800 sLeA sites/µm2, 5 µm sphere adhesion occurs in a “reaction-
limited” regime (RLR) where particles are able to localize to the wall but do not 
effectively adhere due to high disruptive forces acting on them [18]. Thus, these spheres 
enjoyed a longer residence time and lower disruptive forces (on average) at the wall in 
pulsatile profile II relative to laminar flow of the same maximum WSR.  The extensive 
increase in the adhesion of 5 µm aICAM-1 spheres in profile I relative to laminar flow 
can be similarly explained.  Overall, aICAM and aVCAM-spheres displayed lower 
adhesion (all sizes) than observed for sLeA-spheres even with the higher antibody site 
densities on these particles and the lower peak WSRs studied.  This is likely due to the 
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low capture efficiency (i.e. the rate of bond formation) exhibited by the antibody-ICAM-
1/VCAM-1 interactions in flow compared to high on-rates that exist for sLeA-selectin 
interactions [23].   
 For adhesion in the VSFC, particle adhesion increased as particle size increased 
from 0.5 to 5 µm (Fig. 4.2A and Fig. 4.2B). No difference in adhesion was observed 
between 0.2 and 0.5 µm spheres.  Peak microsphere adhesion occurs at the reattachment 
area due to low parallel shear forces and a maximum normal velocity on the wall [19], 
consistent with previous reports of platelets (~ 2 µm) and leukocytes (~ 7-15 µm) 
adhesion in similar VSFC [19, 24].  There also appears to be a significant recirculation-
induced redistribution of particles to the wall in VSFC based on the higher particle 
adhesion far downstream from the step compared to previous observation with straight 
channel laminar flow (no recirculation) under the same shear conditions [18].  
Microspheres also appear to enjoy a higher redistribution to the wall than nanospheres as 
evidenced in their higher “peak-to-far downstream” adhesion ratios.  Overall, pulsatile 
flow in the VSFC did not enhance adhesion when compared with adhesion in laminar 
flow at the same average shear in the VSFC (Fig. 4.2B and Fig. 4.2C); it is likely that 
pulsatile flow disrupts particle distribution associated with the recirculation flow.       
The presence of competing leukocytes in whole blood did not prevent spheres 
from binding – even at their disproportionately higher concentration (~7.5x106 
neutrophils/mL of blood).  The 2 and 4 fold higher adhesion of nano- and 2 µm spheres 
in pulsatile whole blood (Fig. 4.3A) relative to reconstituted blood (Fig. 4.1A) is likely 
due to the difference in hematocrit level between the two, ~45% and 30% Hct 
respectively.  Others have previously reported that the width of the cell-free layer (CFL) 
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that exists near the wall in blood flow decreases with increasing hematocrit due to RBCs 
occupying more volume inside the channel [25]. A smaller CFL in whole blood flow 
results in a more direct contact between RBCs and particles, increasing their 
concentration proximal to the wall, thus promoting higher adhesion. A similar hematocrit 
effect has been reported for platelet adhesion [26].  No hematocrit effect was seen for 
adhesion of 5 µm spheres, which is consistent with previous observations for leukocyte 
(7 – 12 µm in size) adhesion in blood with hematocrit changes in the range studied here 
[10, 27].   Here, it is likely that the CFL is on the order of the 5 µm size and thus direct 
contact between RBCs and spheres is disruptive to binding.  Interestingly, 5 µm spheres 
show a significantly higher adhesion density (~2 fold) at higher whole blood hematocrit 
in the VSFC (Fig. 4.2A and Fig. 4.3B).   This may suggest that the rotational motion 
induced by the sudden expansion at the step creates a different particle distribution 
pattern in whole blood than present in flows (laminar or pulsing) in straight channels as 
previously suggested by others [24].    
It is also likely that RBC aggregation contribute to the adhesion trend in 
reconstituted blood relative to whole blood since the ~1.3 wt% dextran used here is in the 
range of dextran plasma concentrations previously shown to induce RBC aggregration 
particularly at low shear [28]. However, no significance difference in sLeA sphere (0.5 
and 2 µm) binding densities was observed in preliminary head-to-head comparison 
between pulsatile profile I assays utilizing blood reconstituted (30% hct) with dextran-
free plasma and ones with dextran in plasma as shown in Fig. 4.1 (data not shown).   This 
is not to say that dextran-induced RBC aggregation is absent in my assays. Instead, it is 
likely that aggregation effects are minimal since targeted particles are exposed to 
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aggregating conditions, i.e. low shear, for a minimal amount of time (e.g. only ~3 sec in a 
21 sec cycle in pulsatile profile I).  The presence of physical and/or reactive interactions 
between targeted spheres and leukocytes present in whole blood but essentially absent in 
reconstituted blood may also play a role in particle binding, e.g. secondary recruitment of 
spheres by WBCs already bound to ECs as previously reported for particles and 
neutrophils [29]. The absence of such an enhancement in the whole blood binding of 5 
µm spheres (i.e. no increase in particle binding) may be due to steric hindrance associated 
with the relative size of these spheres and leukocytes though data obtained for 
recirculating flow assays suggests otherwise. Overall, detailed experiments are needed to 
fully elucidate the role of particle-WBC synergy in the adhesion of particles of various 
sizes in different types of flow.   
Overall, my results showed that nanospheres in pulsatile and recirculating blood 
flow displayed minimal adhesive interaction at the wall relative to microspheres in in 
vitro experiments with human blood.  This finding suggests that nanospheres have a 
much lower margination efficiency in disturbed human blood flow and thus may not be 
optimum for use as drug carrier or imaging probe in the treatment of atherosclerosis.  
Instead, spheres with 2 µm diameter appear to be optimum for achieving high 
margination to the vessels wall in disturbed bulk blood flow.   
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CHAPTER 5  
 
PARTICLE-CELL DYNAMICS IN BLOOD FLOW- 
IMPLICATIONS FOR VASCULAR-TARGETED DRUG 
DELIVERY 
 
 
 
ABSTRACT 
 
 
The outcome of targeted drug delivery is generally determined from the efficiency 
of vascular-targeted carriers (VTCs) in localizing and adhering (margination) at the 
specific targeted sites. Red blood cells (RBCs) and hemodynamics have been shown to 
dictate VTC behavior in reconstituted blood flow (blood devoid leukocytes and platelets), 
as discussed in the previous chapters. However, other blood cell components in whole 
blood may also affect the VTC margination, yet very limited work has been elucidated. 
Thus, this study aims to investigate the role of leukocytes (WBCs) and platelets on the 
margination of VTC to the vascular wall under physiological blood flows. Specifically, 
inflammation-targeted spherical VTCs, 0.2, 0.5, 2, 5 and 10 µm in diameter, were 
observed for their adhesion on activated endothelial cells via a parallel flow chamber 
(PPFC) in laminar, pulsatile and recirculating blood flow. In general, the binding density 
of spheres in whole blood flow is a function of particle size and is primarily dictated by 
RBCs and WBCs. Specifically, adhesion of nanospheres was minimal compared to 
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microspheres in all flow types studied. Red blood cell can either promote or hinder 
particle adhesion depending on the ratio of cell free layer (CFL) width to particle size. 
Leukocyte tends to prevent microsphere adhesion via (1) competition for the available 
binding space on endothelial wall and (2) physical interaction (rolling motion) with the 
previously bound particles that eventually knock them off from the wall. On the other 
hand, resting platelets have no effect on particle binding due likely to their low adhesion 
at the wall in this study. Overall, in this work, I elucidate the physical and molecular 
dynamics of spherical particles with blood cells in physiological blood flow; my results 
can serve as a road map for designing efficient VTCs for imaging and targeted drug 
delivery applicable in many human diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
Contents of this chapter are prepared for submission as Charoenphol P and Eniola-Adefeso O. Particle-Cell 
Dynamics in Blood flow- Implications for Vascular-Targeted Drug Delivery.   
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5.1 Introduction 
The notion of targeted delivery of therapeutics/imaging agents, the process of 
delivering drugs/imaging agents encapsulated within (or attached to) a carrier to a targeted 
site, is now a norm in medicine, representing a mainstay in the diagnosis and treatment of 
many chronic and serious human ailments.  In many cases, the vascular wall endothelium 
(a monolayer of endothelial cells lining the lumen of blood vessels) is the target of such 
engineered delivery system since it participates in several physiological and pathological 
processes, including angiogenesis and inflammation [1-3], and represents a direct contact 
with the bloodstream that is the most common route for carrier entry into the body. The 
local delivery of anti-angiogenic and pro-angiogenic therapies to the vascular wall in 
cancer and ischemic cardiovascular diseases, respectively, are classic examples of 
vascular-targeted drug delivery [4]. Similarly, drug/imaging carriers are often designed to 
target inflammation afflicted vascular wall in several serious conditions including 
coronary artery disease stemming from atherosclerosis [5, 6].  
Overall, appropriately designed vascular-targeted carriers (VTCs) must possess the 
capacity to (1) easily navigate the bloodstream while maintaining hemostasis, (2) avoid 
rapid immune clearance, (3) localize from the bloodstream to the vessel wall in target 
vessel/organ and (4) bind at the vascular wall via targeting chemistry (target specificity).  
The first two attributes have been well teased out. For instance, a nanometer size range 
and surface pegylation significantly improve the in vivo circulation of particulate carriers 
[7], and several publications in the literature have focused on investigating the possible 
toxicology effect of carriers (particularly nanocarriers) on blood cells such as hemolysis, 
thrombogenicity and complement activation [8, 9]. The last two of the highlighted 
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attributes constitute carrier margination (localization and adhesion) but have typically 
been studied in the context of target specificity only (adhesion) due to the assumption that 
all particulate carriers can localize to the vascular wall from blood flow. This assumption 
likely stems from earlier studies showing red blood cells (RBC), the most abundant cell 
components of blood, promote the adhesion of white blood cells (WBCs) [10, 11], platelet 
[12, 13] and microparticles [14] by preferentially align at the center of blood flow while 
pushing other cells or particles to a RBC-free plasma layer (CFL) near the vascular wall. 
However, we previously demonstrated via in vitro parallel plate flow chamber (PPFC) 
assays with human blood and in vivo in a mouse model of atherosclerosis that particle 
binding from flow to inflamed endothelial cells was enhanced in the presence of human 
RBCs only for microspheres with diameter greater than 1 µm [15, 16]. Nanospheres at the 
same particle-surface targeting ligand density as microspheres showed low binding in 
blood flow due to their high entrapment in the RBC core during blood flow that result in 
their low localization to the endothelial wall.  However, our previous in vitro assays were 
with reconstituted human blood (RBCs in plasma with no platelets or WBCs).  Thus, it is 
not clear whether the observed patterns in reconstituted blood or in vivo in mice would 
translate to adhesion patterns in human whole blood since WBCs and platelets also 
localized to the CFL area and thus can interact with VTCs to alter their binding.  
Indeed, very limited studies have focused on the effects of blood cells, particularly 
interactions of leukocytes and platelets, on particles/VTCs dynamics in blood flow and 
their subsequent adhesion at the vascular wall.  Existing works investigating the interplay 
between platelets and leukocytes have shown that activated platelets and leukocytes 
themselves can enhance leukocyte recruitment to the vascular wall by their molecular 
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interactions [17, 18].  Though VTCs are often engineered to mimic leukocytes, the 
interaction of platelets and leukocytes with these carriers and their effect on carrier 
adhesion to the vascular wall may not necessarily be similar to the ones reported for 
leukocyte adhesion due to differences in their sizes (particularly at the nano-range) and 
viscoelastic properties. Thus, it is imperative that the synergy between WBCs/platelets and 
VTCs that eventual effect carrier margination to the vascular wall, either by physical or 
molecular interaction, be elucidated in order to inform the design of high performing 
VTCs.  
In this work, we elucidate drug carrier-blood cell synergy and how this potentially 
affects VTCs margination to the vascular wall. We specifically focus on the effects of 
RBCs, WBCs and platelets on the binding of Sialyl Lewis A- or aICAM- coated 
polystyrene (PS) spheres of different sizes to inflamed human umbilical vein endothelial 
cells (HUVECs) via PPFC assays, representing the targeting of endothelial-expressed 
selectins and ICAM-1 molecules, respectively. In this work, we predominantly focus on 
Sialyl LewisA (sLeA), a member of a class of carbohydrates molecules that have been 
previously proposed for use to target carriers in several diseases [19-22], due to its 
favorable binding kinetic in flow and since it would represent the highest possibility for 
interactions with leukocyte and platelets that also express considerable levels of selectin 
molecules.  We report here that RBCs and WBCs specifically alter the adhesion of 
spherical particles depending on their size and type of blood flow, i.e. laminar, pulsatile 
and recirculating human blood flow, while platelets exhibited no effects on particle 
adhesion for all conditions studied.    
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5.2 Results 
The experimental set up used in this chapter is described in detail in Chapter 2. 
 
5.2.1 Effect of RBCs on particle adhesion in reconstituted blood flow 
The volume composition (hematocrit) of RBCs is known to vary from high values 
in medium and large vessels to low values in the capillaries. To elucidate the role of 
hematocrit levels (%Hct) on particle binding to endothelial cells (ECs) from blood flow, 
the margination of particle were conducted in reconstituted blood, i.e. blood devoid of 
platelets and WBCs, having different hematocrits.  Fig. 5.1 shows the binding density of 
sLeA-coated particles on activated ECs after a given period of laminar (at 500 s-1 of 
WSR), pulsatile (with backward and forward flow with peak WSR at 1000 s-1) and 
recirculating (200 s-1 of WSR at far downstream region) reconstituted blood flow for 30 
and 45% Hct values.  The binding density of particles in laminar blood flow with 30 
%Hct significantly increased with increase in particle size from 500 nm to 5 µm (Fig. 
5.1A).  There was no significant difference in the adhesion density observed for 200 nm 
particles relative to 500 nm ones.  Also, particle adhesion density significantly decreased 
(~2.6 fold) with the increase in particle size from 5 to 10 µm. An increase in blood 
hematocrit to 45% resulted in only a slight alteration in particle binding trend where 
adhesion density only significantly increased with particle size increases from 0.2 to 2 
µm.  The increase in particle size from 2 to 5 µm did not yield a significant increase in 
particle binding, and a decrease in binding density was observed with the increase in size 
from 5 to 10 µm similar to observation with the 30 %Hct laminar flow.    
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Figure 5.1 Adhesion of sLeA-particle in (A) laminar (WSR = 500s-1, 5 mins), (B) 
pulsatile (profile I, peaked WSR = 1000 s-1, 15 mins) and (C) recirculating 
(WSR = 200 s-1, 5 min) reconstituted blood (RB) flow at 30% (open) and 45% 
Hct (close).  
 Dash line and solid line represent observed reattachment point at 30% and 
45% Hct in the VSFC, respectively.   
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Overall, an increase in hematocrit from 30 to 45% resulted in no significant effect 
on the laminar blood flow binding of 0.2 and 10 µm particles while significantly 
enhancing the binding of 0.5 and 2 µm spheres by 205 and 23%, respectively.   The 
laminar flow binding of 5 µm particles was slightly (18%) hindered (p value = 0.004) 
with the same magnitude of increase in reconstituted blood hematocrit. 
The binding trend observed for particles in pulsatile reconstituted blood flow at 30 
%Hct was similar to observation for laminar flow at 45% Hct.  As shown in Fig. 5.1B, 
the adhesion of spheres significantly increased with increase in particle size from 0.2 to 2 
µm.  There was no significant change in binding with the increase in particle size from 2 
to 5 µm.  However, an increase in reconstituted blood hematocrit to 45% for pulsatile 
flow resulted in a significant decrease in the binding of 5 µm spheres relative to the 2 µm 
ones.  Spheres of 10 µm diameter did not exhibit any adhesion in pulsatile flow at the two 
%Hct tested.  Overall, only the 2 µm spheres saw a net gain in their adhesion density with 
increase in hematocrit from 30 to 45% in pulsatile flow; the adhesion of other spheres 
tested did not change with increase in hematocrit for this flow type.  
For reconstituted blood flow in the VSFC, minimal particle binding to ECs was 
observed in the region near the step (0 – 50 µm downstream of step) as shown in Fig. 
5.1C.  The binding density for all particle sizes, however, increased with increase in 
distance from the step up to the region just beyond the flow reattachment point – beyond 
which flow moves forward and towards a laminar profile (~200 µm from step for both 30 
and 45% Hct). There was also no difference in the adhesion of all particles between the 
two RBC compositions studied in the recirculation zone (i.e. upstream of reattachment 
point). Beyond the flow reattachment point, particle binding either plateaued or decreased 
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with increase in distance away from the step depending on the size of the particles and 
the composition of RBCs.  Specifically, 2 and 5 µm spheres saw increases in their 
binding density beyond flow reattachment with the increase in hematocrit from 30 to 
45% (237% and 72%, respectively) due to the significant drop in their binding from peak 
value with the 30% Hct blood flow while particle binding in the 45% Hct blood remained 
constant.  No effect of RBC composition was observed for nanospheres and 10 µm 
spheres in the area immediate of the flow reattachment. In the far downstream region of 
the VSFC (> 5000 µm from the step) where flow was again fully developed, particle 
adhesion trend relative to particle size was unchanged from observation in the 
recirculation zone – there was no significant difference (p<0.01; student’s t test) in the 
magnitude of adhesion observed for all particles interacting between the two RBC 
compositions studied.  
5.2.2   Effect of white blood cell (WBCs) on particle adhesion in whole blood flow 
To probe the contribution of WBCs (leukocytes) to particle adhesion patterns in 
blood flow, the margination of spheres of different sizes were observed in leukocyte-
depleted blood (LDB)  (RBC and platelets in plasma) relative to whole blood.  Since 
dextran is necessary for a high-yield WBC removal from whole blood, dextran was added 
to whole blood in the same concentration (~ 0.6% w/v) as with LDB to allow direct 
comparison. Fig. 5.2 shows the binding density of particles in laminar, pulsatile and 
recirculating LDB relative to whole blood.  In general, the adhesion trend relative to 
particle size was not significantly altered in LDB relative to whole blood for all flow type 
studied.  The adhesion of smaller sized spheres was also not significantly altered with the 
removal of leukocytes from whole blood for all flow types.      
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Figure 5.2 Adhesion of sLeA-particle in (A) laminar (WSR = 500s-1, 5 mins), (B) 
pulsatile (profile I, peaked WSR = 1000 s-1, 15 mins) and (C) recirculating 
(WSR = 200 s-1, 5 min) leukocyte-depleted blood (LDB, open) and whole 
blood  (WB+D, close) flow. 
Dash line represents observed reattachment point in the VSFC. Both blood 
flow conditions have the same % Hct and have equal amount of dextran.   
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However, the presence of WBCs in blood negatively impact binding of 10 µm spheres in 
laminar flow since the binding density for these particles was significantly higher in 
laminar flow with LDB relative to whole blood as shown in Fig. 5.2A   Both the 2 and 5 
µm spheres similarly exhibited higher adhesion in pulsatile LDB relative to whole blood 
(~70% for both sizes) as shown in Fig. 5.2B. For experiments in the VSFC (Fig. 5.2C), 
only 2 µm-sized spheres were observed to show significantly higher (78%; p = 0.003) in 
recirculating LDB flow relative to the whole blood in regions just beyond flow 
reattachment. At far downstream of recirculation in the VSFC, the effect of WBC 
removal mirrored observation in laminar flow in the straight channel where only 10 µm 
spheres exhibited differential adhesion between the two types of blood. The adhesion of 2 
and 5 µm spheres at far downstream of recirculation was not significant between LDB 
and whole blood (p value = 0.02 and 0.05, respectively).    
 
5.2.3 Rate of microsphere attachment in WBC depleted blood (LDB) 
Fig. 5.3 shows the rate of microsphere and leukocyte attachment to EC monolayer 
from pulsatile LDB and whole blood flow for 15 min.  As shown, the adhesion of 2 µm 
spheres in LDB and whole blood increased over time and were not significant from each 
other for all time points up to 13 mins (Fig. 5.3A).  At longer times, the adhesion of 2 µm 
spheres in whole blood appear to plateau while the ones in LDB continued to exhibit a 
linear increase with time.   The rate of adhesion for 5 µm spheres in LDB was similar to 
the adhesion rate in whole blood only at flow times less than 6 mins (Fig. 5.3B).    
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Figure 5.3 Rate of particle and white blood cell (leukocyte) attachment in pulsatile flow 
(profile I, peak WSR 1000 s-1, 15 mins): (A) 2 µm and WBC, and (B) 5 µm 
and WBC binding in leukocyte-depleted blood (LDB) and whole blood (WB). 
Dash line represents observed reattachment point in the VSFC. Both blood 
flow conditions have the same % Hct and have equal amount of dextran.  
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The adhesion of 5 µm in LDB eventually reached a plateau at 8 min of flow; however, 
their adhesion in whole blood appear to decrease with increase in flow time (slope ≈ -
10.23) to a minimum at between 12 and 14 min of flow.  Overall, the rate of WBC 
adhesion in whole blood increased with time up to a maximum of ~ 650 sites/µm2 at 10 
min irrespective of whether 2 or 5 µm sLeA spheres are present in flow.   
 
5.2.4 Dynamics of WBCs interference with microsphere adhesion in blood flow 
To probe whether the reduced microsphere adhesion seen in whole blood relative 
to LDB is due to molecular interaction associated with the sLeA ligand on microspheres 
effecting microsphere-WBC aggregations via molecules-expressed on leukocytes (e.g. L-
selectin), some adhesion assays were conducted with 5 µm spheres coated with a 
monoclonal antibody against ICAM-1 (expressed abundantly on ECs but not by WBCs) 
at a high enough density to support their adhesion to ECs from blood flow pulsing 
between -500 and 500 s-1 of WSR (Fig. 5.4). The slower reaction kinetics between the 
antibody and ICAM-1 limits evaluation of the adhesion of anti-ICAM-1 (aICAM-1) 
microspheres in pulsatile flow with peak WSR at 1000 s-1; i.e. only minimal binding is 
observed. Similar to sLeA- microspheres, the adhesion of both the 2 and 5 µm aICAM-
microspheres in whole blood was lower compared to their adhesion in LDB (Fig. 5.4C), 
which may suggest that the interference of WBCs with microspheres binding in whole 
blood is not due to molecular interaction/aggregation between the two, either in flow or at 
the endothelial surface. No negative change in adhesion density with time was observed 
for aICAM microspheres in contrast to sLeA spheres (Fig. 5.4A and 5.4B). 
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Figure 5.4 Adhesion of aICAM-particle in pulsatile leukocyte-depleted blood (LDB) and 
whole blood (WB) flow (profile I, peak WSR 500 s-1, 15 mins). Rate of (A) 2 
µm and (B) 5 µm aICAM particle attachment and (C) particle binding at 15 
mins in LDB and WB. 
Both blood flow conditions have the same % Hct and have equal amount of 
dextran. * p<0.01 compared to particle binding in LDB.  
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In the absence of molecular interactions, physical competition for adhesion to the 
inflamed ECs between WBC and microspheres may possibly hinder microsphere 
adhesion in whole blood. To determine whether this, i.e. the physical removal of WBCs 
from blood creating a void in the cell-free layer at the wall, results in the higher binding 
of microspheres in LDB relative to whole blood, assays were conducted with 5 µm 
spheres in pulsatile LDB flow having non-functional PLGA microspheres (no adhesion 
ligand) added in at the same concentration (4 x 106/mL) and size distribution (average 
size = 8 µm) as the depleted WBCs (Fig. 5.5). The attachment rate and adhesion densities 
of 5 µm-sLeA spheres under pulsatile flow in LDB with non-targeted PLGA spheres were 
not significantly different from their adhesion in LDB alone (p value = 0.18) but were 
significantly higher than values obtained for adhesion in whole blood. This suggests that 
the interference of WBCs with microsphere binding in whole blood likely occurs at the 
point of binding (i.e. competition) at the EC wall rather than in flow. The negative slope 
observed for the rate of attachment for 5 µm spheres in whole blood may also suggest an 
active displacement of microspheres by WBCs in whole blood flow in addition to 
competition for binding (Fig. 5.3B).   To probe this further, video records of adhesion for 
5 µm spheres in pulsatile whole blood flow assays were analyzed for particle-
microspheres interaction at the wall.  Indeed, several collisions between WBCs and these 
particles were observed and resulted in the detachment of previously bound spheres.  This 
collision-induced particle detachment likely results from higher drag force acting on 
particles at the instance of collision to overcome the previously sufficient adhesive force 
at the wall. 
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Figure 5.5 Adhesion of sLeA-particle (1000 site/µm2) in pulsatile leukocyte-depleted 
blood alone and with non-functional PLGA microspheres (LDB, 
LDB+PLGA) and whole blood (WB) flow (profile I, WSR = 1,000 s-1, 15 
mins). (A) Rate of 5 µm sLeA-particle attachment and (B) Particle binding at 
15 mins. Insert B = PLGA particle size distribution. 
All blood flow conditions have the same % Hct and have equal amount of 
dextran. * p<0.01 compared to particle binding in LDB.   
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To confirm this hypothesis, 2 and 5 µm spheres with twice higher density of sLeA, 
2000 sites/µm2, were observed in whole blood pulsatile flow with peak WSR 1000 s-1 
(Fig. 5.6).  There was no significant difference in the attachment rate and adhesion of 
microspheres between pulsatile flow with LDB and whole blood for 2 µm spheres at this 
higher density of sLeA.  For 5 µm spheres, the higher ligand density resulted in a 
significant reduction in the difference in adhesion density between LDB and whole 
blood, from 70% down to 27% difference (Fig. 5.6C).  A second set of experiments with 
the adhesion of 2 and 5 µm observed in pulsatile flow at a lower peak WSR of 500 s-1 
(Fig. 5.7) similarly showed no significant difference in the attachment rate and adhesion 
of these spheres between LDB and whole blood.  
5.2.5 Effect of platelets and dextran on particle adhesion in whole blood flow 
Fig. 5.8 shows the adhesion of sLeA spheres in laminar, pulsatile and recirculating 
platelet-depleted blood (PDB) relative to whole blood.  Across all blood flow patterns 
tested, the binding density of sLeA-spheres of all sizes in platelet-depleted blood was not 
significantly different from the binding density obtained for the same particles in whole 
blood. This would suggest that any interactions between platelets and VTCs that exist in 
whole blood minimally affect the margination of these carriers to the vascular wall.   An 
interesting observation, however, from the whole blood experiments shown in Fig. 5.8 is 
that the presence of dextran in the whole blood flow as shown in Fig. 5.2 negatively 
affects the binding of 2 µm spheres in all types of blood flows while having no effect on 
all other spherical sizes.   
.   
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Figure 5.6 Adhesion of sLeA-particle (2000 site/µm2) in pulsatile leukocyte-depleted 
blood (LDB) and whole blood (WB) flow (profile I, peak WSR 1000 s-1, 15 
mins). Rate of (A) 2 µm and (B) 5 µm sLeA-particle attachment and (C) 
particle binding at 15 mins in LDB and WB.  
Both blood flow conditions have the same % Hct and have equal amount of 
dextran. * p<0.01 compared to particle binding in LDB.   
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Figure 5.7 Adhesion of sLeA-particle (1000 site/µm2) in pulsatile leukocyte-depleted 
blood (LDB) and whole blood (WB) flow (profile I, peak WSR 500 s-1, 15 
mins). Rate of (A) 2 µm and (B) 5 µm sLeA-particle attachment and (C) 
particle binding at 15 mins in LDB and WB. 
Both blood flow conditions have the same % Hct and have equal amount of 
dextran. * p<0.01 compared to particle binding in LDB.   
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Figure 5.8 Adhesion of sLeA-particle in (A) laminar (WSR = 500s-1, 5 mins) (B) pulsatile 
(profile I, peaked WSR = 1000 s-1, 15 mins) and (C) recirculating (WSR = 
200 s-1, 5 min) platelet-depleted blood (PDB, open) and whole blood  (WB, 
close) flow.  
Dash line represents observed reattachment point in the VSFC. Both blood 
flow conditions have the same % Hct.   
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The effect of dextran on 2 µm spheres is the most pronounced in the pulsatile blood flow 
profile with as much as 42% reduction in binding density in the presence of dextran. 
5.3 Discussion 
Targeting of particulate carriers to the vascular wall for imaging and delivery of 
drugs remains attractive for the diagnosis and treatment of several diseases. In general, 
targeting of imaging carrier can provide enhanced resolution and sensitivity through 
concentration of imaging agents at the diseased site. Similarly, vascular-targeted drug 
carriers can provide safer (localized delivery) and more efficient (reduced drug cargo) 
intervention through localization and release of encapsulated therapeutics at the target 
sites. While the concept of targeted drug delivery system dates back several decades now, 
only a handful of these technologies have made it to clinical use.   In fact, many novel 
therapeutics/delivery systems that show great promise in preclinical research at the bench 
and in animal models have failed in the clinics [23, 24]. This gap between preclinical 
research and clinical outcomes may be, in part, due to, carrier design strategies heavily 
focused on target epitope while neglecting key parameters such as the dynamic forces 
associated with blood flow, hemorheology and blood cell-carriers interactions that all 
may significantly impact the capacity for vascular-targeted carriers (VTCs) to interact 
with the vascular wall.  Overall, VTCs with optimized targeting moiety but lacking the 
capacity to marginate (localize and adhere) to the blood vessel wall would likely deliver 
their cargo systemically rather at the intended site.  A detail understanding of interactions 
between VTCs and blood cells in different types of blood flow patterns that exist in the 
human circulation would help inform the design of VTCs for optimal functionality in 
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humans.  Herein, we evaluated the role of RBCs, leukocytes and platelets on the binding 
of inflammation-targeted polystyrene spherical particles sized from 200 nm to 10 µm 
diameter to inflamed endothelial cell (EC) monolayers via parallel plate flow assays with 
physiological blood flow conditions. We show that the role of blood cells in dictating the 
adhesion of spherical particles to the wall from blood flow is coupled to the particle size 
and/or targeting ligands, blood shear rate and flow types. 
In general, the margination of nanospheres to EC monolayers was minimal 
relative to the margination of small microspheres in all types of flow patterns and blood 
compositions.  This observation is in agreement with our previous observation in 
reconstituted blood (RBC only in plasma) flow and is due to the propensity for RBCs to 
preferentially migrate and align in the center of flow while driving microspheres to the 
CFL adjacent to the vascular wall allowing for their frequent contact with endothelium 
whereas nanospheres are entrapped within the RBC core [15, 16, 25]. Previously 
presented control experiments with nanospheres endowed with 2.5 times higher sLeA 
ligand density than microspheres tested at the same shear rate showing no significant 
increase in their adhesion density confirmed that transport to the wall rather than reaction 
at the wall was indeed limiting nanosphere adhesion [16]. The 2 µm spherical diameter 
appears to be the most optimum size for margination in laminar and pulsatile whole blood 
flow, particularly at high wall shear rates (during the peak WSR of pulsatile flow), likely 
due to the high slip velocity (i.e. the velocity of particles before forming a bond at the 
wall [26]) and disruptive force experienced by 5 and 10 µm spheres during flow and at 
the reaction site respectively, i.e. adhesion is reaction rather than transport limited.  
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In recirculating blood flow, particle binding, particularly for microspheres, 
increased with distance away from the step, peaking slightly beyond the reattachment 
point and decreasing toward far downstream where flow is laminar (Fig. 5.1C). In the 
vortex region, there are two directional velocities, the axial velocity parallel to the wall 
(Vx) and the normal velocity (Vz) with directions acting away and toward to the wall at 
the step and reattachment point, respectively [27]. Particles are therefore brought towards 
the wall with the flow streamline at the reattachment point.  This is in part responsible for 
the observation of peak adhesion beyond the reattachment point.  The accumulation of 
particles at the wall proximity in this region appear to disproportionally favor small to 
medium-sized microspheres over nanospheres as suggested by the 4 and 13 folds 
difference in the adhesion density between 2 and 5 µm relative to the 0.5 µm spheres, 
respectively, compared to only 3 and 6 folds difference between these microspheres and 
0.5 µm spheres at the far downstream region (Fig. 5.2C). This particle distribution trend 
in the recirculation flow is likely due to the higher rotational motion inducing higher 
frequency and magnitude of collision between microparticles and RBCs.  However, the 
low WSR of 200 s-1, i.e. low blood flow rate, in the recirculation channel also likely 
contribute to the resurgence of the 5 µm spheres as the optimal size for binding in the 
VSFC though a similar trend was not seen with laminar blood flow at 200 s-1 in a straight 
channel of similar height to the VSFC (data not shown).  Accordingly, microspheres are 
favored for binding relative to nanospheres in all flow types.  It is curious that the 
recirculating flow, which presumably interferes with the well-packed RBC cores, also 
overwhelming enhance the adhesion of microspheres over nanospheres.    
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The role of RBC volume fraction on carrier margination is apparent in Fig. 5.1. 
The slight change in particle binding pattern observed in laminar reconstituted blood 
flows with 45% Hct relative to 30% Hct is likely due to the shrinking of the plasma CFL 
with increase in blood hematocrit.  Several studies have indicated the importance of CFL 
on the adhesion of blood cells and particle to the vascular wall [10]. The width of this 
CFL has been reported to vary in the range between 2.5 – 7 µm depending on several 
factors including the hematocrit level, blood vessel size and WSR [28-30].  An increase 
in blood hematocrit enlarges the RBC core thereby reducing the CFL width [30]. Thus, at 
a higher hematocrit, particles would localize into a thinner CFL resulting more frequent 
collision between particles and with RBCs. The increase in collision induces the lateral 
migration of particles towards the endothelium, which eventually leads to their binding at 
the wall, as seen with the increase of the binding observed for the 0.5 and 2 µm spheres 
with higher hematocrit. However, increase in particle collision in the CFL can also 
prevent the particle binding, particularly for larger microspheres. Specifically, a large 
number of particles at the wall would increase competition for the binding space and/or 
provide redundant collision that leads to the detachment of previously bound particles 
from the wall, as observed with the decrease in the binding of 5 µm spheres at higher 
RBC volume fraction. This also likely explains the disproportionately higher effect of 
increased hematocrit on the binding density of 0.5 µm (~ 205%) relative to 2 µm (23 %) 
spheres, in that the nanospheres likely experience minimal negative collision due to low 
initial concentration at the wall and their size. The lack of a hematocrit effect on the 
adhesion of 0.2 µm spheres across all flow types may be due to a combination of their 
extremely poor localization and their significantly smaller size compared to the CFL 
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width.  The observed effects of RBC on particle binding here also agree well with 
previous publications evaluating the effect of blood hematocrit on the adhesion of blood 
cells in laminar flow. Specifically, the binding of platelet (~ 2 µm) increases as blood 
hematocrit changes from 0 to 50 % whereas leukocyte (~ 8 -12 µm) adhesion increases 
with blood hematocrit only changes from 0 to 30%. Further increase in hematocrit from 
30 to 60% Hct had no effect on leukocyte adhesion [10, 12].  The lack of a negative 
effect of hematocrit on WBC adhesion at higher value as was found for the 5 µm spheres 
in laminar flow in this work is likely due to the deformable nature of the former that may 
help minimize the negative force imparted by collision.  
It is not surprising that the increase in blood hematocrit only enhanced the 
margination of 2 µm spheres in pulsatile flow while having no effect on other particle 
sizes. The pulsing of blood flow in a backward to forward direction around zero shear 
likely resulted in transient CFL width, where the CFL become larger as WSR decreases 
[28, 29]. Thus, the increase in CFL width during periods of low WSR may cancel the 
gain observed for the 0.5 µm spheres in laminar flow.  Meanwhile, a larger CFL width 
would lower the collision frequency of large particles (5 µm), which may counterbalance 
the smaller CFL effect gained from increasing % Hct. Thus, increasing blood hematocrits 
had no effect on the binding of 0.5 and 5 µm in pulsatile flow. The increase in %Hct in 
recirculating blood flow only promoted the binding of 2 and 5 µm spheres in regions 
beyond the reattachment point. The lack of a hematocrit effect on the binding of 10 µm 
spheres, however, is probably due to excessive collision between large particles in the 
small CFL preventing them from binding.  Though, it is possible that these particles 
formed aggregates and/or are large enough for a significant portion of them to remain 
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trapped in the recirculation zone.   Indeed, the overall adhesion of 10 µm spheres in 
recirculating reconstituted blood flow with the two hematocrits tested was low compared 
to other microspheres. 
The comparison of particle binding observed in leukocyte-depleted blood (LDB) 
and whole blood flow in Fig. 5.2 showed that the presence of WBCs in blood tended to 
negatively impact microsphere binding whereas no WBC effects were observed for the 
binding of nanospheres in all flow types. The presence of WBCs in blood negatively 
impacted the binding of 10 µm spheres in laminar flow of the straight channels at 500 s-1 
of WSR and that of 2 and 5 µm in pulsatile flow with peak WSR at 1000 s-1.  Observation 
in these two types of flows would suggest that the impact of WBCs on carrier binding is 
coupled to the shear force impacted by flow, since smaller microspheres saw no effect at 
500 s-1 of laminar wall shear whereas their adhesion were affected in flow with peak 
WSR at 1000 s-1. The combination of low shear and unique cell/particle 
distribution/collision pattern in the vortex and flow reattachment regions of the VSFC 
again contributed to the lack of a WBC effect on the adhesion of particles of all sizes 
since the WBC-effect trend at the far downstream region of the VSFC mirrored ones 
observed in straight channels with laminar flow.  Indeed, others have reported a different 
dynamic of WBCs binding in the VSFCs similar to the one used in this study relative to 
straight channels of similar heights and WSR [11]. 
The rate of attachment data presented in Fig. 5.3 suggests that the impact of 
WBCs on microspheres adhesion is linked to a surface “saturation effect”.  The adhesion 
of 2 and 5 µm spheres in pulsatile whole blood flow plateaued about 13 and 5 mins in the 
15 min duration of pulsatile, respectively, while their binding in pulsatile LDB exhibited 
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no plateau or enjoyed a longer period of linear increase.  In whole blood the rate of WBC 
binding was similar observed to reach a plateau about 10 mins in flow. This particle and 
WBC rate of attachment pattern suggest minimal competition between microspheres and 
leukocytes during early flow times when the EC substrate provides ample binding space.  
As the monolayer surface continued to be populated, however, particles and WBCs begin 
to compete to occupy the few available binding spaces on endothelial cells.  With the 
smaller ratio of WBC to particle diameter for the 5 µm spheres, it makes sense that the 
surface saturation effect was observed at earlier time points for these spheres.  However, 
the negative adhesion observed for 5 µm spheres as leukocyte binding increased 
suggested that leukocytes competed off previously bound spheres. This was confirmed by 
observation of WBC collision with previously bound 5 um spheres that resulted in their 
detachment from video record of experiments (see Supplemental Video for the paper). 
Control experiments with anti-ICAM-1 coated beads suggested that molecular 
interactions between microspheres and WBCs did not contribute to the decreased in 
microsphere adhesion in whole blood (Fig. 5.4C) since their adhesion is also significantly 
lower in whole blood relative to LDB though no appreciable amount of ICAM-1 is 
expressed by leukocyte to justify the possibility of molecular interaction mediated by 
anti-ICAM-1. The lack of a negative rate of attachment observed for aICAM-1 spheres is 
due to the stronger adhesion force, i.e. low off-rate, exhibited by the aICAM-ICAM-1 
interaction resulting in no removal of bound microspheres upon WBC collision (Fig. 
5.4A and 5.4B). Overall, the observation of a similar level of binding of WBCs in 
pulsatile whole blood in the presence of 2 and 5 µm spheres would suggest that spheres 
may have no impact on the adhesion of leukocytes. This observation is important for 
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imaging and drug delivery applications since it indicates that the introduction of vascular-
targeted carrier in the blood circulatory system even with interactive ligands such as sLeA 
would not enhance or prevent the margination of WBC to endothelial cells during 
inflammation in vivo.  
The experiments with non-adhesive spheres, at the same level as normal 
leukocyte concentration, replacing WBCs in whole blood suggested that the collision and 
competition of spheres and leukocytes in flow minimally contribute to the reduction of 
particle binding in whole blood (Fig. 5.5), i.e. the negative impact of WBCs on 
microsphere binding primarily occurred at the endothelial wall by WBCs knocking off 
previously bound spheres and/or possessing favorable adhesion kinetics to successfully 
compete out larger spheres for adhesion. This hypothesis was further confirmed by 
observing the binding of spheres with twice higher sLeA ligands than originally used for 
pulsatile flow experiments with peak WSR 1000 s-1 as presented in Fig. 5.3 where the 
attachment rates (Fig. 5.6A) and the adhesion levels of 2 µm spheres in LDB and whole 
blood were not significantly different (Fig. 5.6C) from each other. The residual reduction 
in the adhesion of 5 µm spheres in whole blood relative to LDB, i.e. ~ 27% decrease for 
2000 site/µm2 versus 70% decrease for 1000 site/µm2 sLeA-spheres suggested that higher 
adhesive force on 5 µm may be needed to withstand the detachment in whole blood under 
high WSR. Moreover, the binding of sLeA spheres (with 1000 sLeA site/µm2) observed in 
pulsatile flow with lower peak WSR (500 s-1) as well as in laminar flow (Fig. 5.2A) 
similarly resulted in no significant differences between microsphere adhesion rate (Fig. 
5.7A and 5.7B) and binding density in LDB and whole blood at this lower average 
disruptive force (Fig. 5.7C). These results suggest that leukocyte would have a minimal 
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impact on the binding of spheres that have adequate adhesive forces to withstand the drag 
force impacted by collision with WBCs. Since the drag force on the bound particle can 
increase with particle size, thus, this can explain why we observed the negative effect of 
leukocyte on 10 µm binding at lower shear rate in laminar flow in both straight channel 
(WSR 500 s-1) and far downstream of the step channel (WSR 200 s-1) (Fig. 5.2). 
The presence of dextran in WB for the LDB flow experiments had no significant 
effect on particle binding for most sizes in all flow types as seen with the similar particle 
binding density in whole blood with (Fig. 5.2) and without dextran (Fig. 5.8) with the 
exception of the 2 µm spherical size. The binding density of 2 µm in whole blood with 
dextran was lower relative to whole blood alone in all flow types evaluated (22%, 42% 
and 35% in laminar, pulsatile and recirculating flow, respectively). Because the average 
size of CFL is about 2.5-7 µm in width, thus the small change in CFL width is likely to 
greatly effect the binding of spheres in this size range, as previously shown that 2 µm was 
the most susceptible size affected by the change in CFL. Dextran is a large carbohydrate 
molecule that can induce RBC aggregation under low shear rate, while having little effect 
on RBC deformation under shear rate greater than 100 s-1 [31, 32]. Since the pulsatile 
profile utilized in this study were pulsed around the zero shear, the addition of dextran to 
whole blood then allowed the increase of RBC aggregation during low shear resulting in 
the increase in cell free layer (CFL) width. This wider CFL then negatively affected the 
binding of 2 µm in pulsatile whole blood flow with dextran. Though dextran had a 
minimal effect on RBC aggregation under high shear flow in laminar (WSR 500 s-1) and 
recirculating flow (WSR 200 s-1), the addition of dextran can increase the viscosity of 
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whole blood which then can negatively effect the particle binding, particularly the 
susceptible sphere size.  
 Platelets were found to have no significant effect on the binding of all sphere sizes 
in all flow types (Fig. 5.8). Though, platelet is able to localize into the CFL as with 
leukocyte and particle; however, due to its small size and disc shape that tends to 
minimize the interaction with other cells and particles, the collision between platelet and 
particles in the CFL may be minimal and thus having no effect on particle behavior. 
Moreover, the majority of platelet in whole blood is unactivated (in resting state), i.e. no 
P-selectin expression; thus, platelet may have minimal molecular interaction with particle 
and leukocyte [33]. In addition, in this study, platelets had a minimal binding on 
endothelium since endothelial cells were activated via IL1-β for 4 hrs, which E-selectin 
and ICAM-1 are mostly upregulated; these molecules are not responsible for platelet 
adhesion [33].  
 
 In summary, this study elucidated the implication of blood cells and particle 
dynamics on the efficacy of particle binding in physiological blood flow. Our results 
suggested that RBC plays an important role on dictating particle binding by creating the 
cell free layer (CFL) at the wall proximity. Leukocyte tends to compete with 
microspheres for binding by occupying the binding space on the inflamed EC monolayer 
and negatively impact particle binding, especially microspheres, via their collision 
motion that can increase the drag force on bound particles. Platelets have a minimal 
effect on particle binding likely due to its resting condition in whole blood and minimal 
adhesion on endothelium.  
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CHAPTER 6  
 
EFFECT OF RED BLOOD CELL SIZE ON THE BINDING 
EFFICACY OF SPHERICAL VASCULAR-TARGETED 
DRUG CARRIER  
 
 
 
ABSTRACT 
 
 
Several animal models have been extensively used in experimental researches 
including in the fields of imaging and vascular-targeted drug delivery. Despite the 
comparable physiological environment of animal models and human relative to an in 
vitro assay, there are still many variations that can significantly impact experimental 
results relative to human system such as differences in hemorheology, hemodynamics 
and the structure of vasculature. Here, this study aims to investigate the role of 
hemorheology of various animal models and human on dictating the binding efficiency of 
spherical vascular-targeted drug carriers (VTDCs) at the wall in physiological blood 
flow. Specifically, the adhesion of sLeA-coated particles, 0.2, 0.5, 2 and 5 µm, to 
inflamed endothelial cells monolayers were conducted via a parallel plate flow chamber 
assay (PPFC). Particle binding was observed in washed blood (red blood cells (RBCs) 
suspended in saline) and whole blood in laminar, pulsatile and recirculating flow. Our 
results suggest that RBCs dictate the particle binding in blood flow by aligning at the 
  119 
flow center and forming the cell free layer (CFL) at the wall vicinity. The CFL width 
may vary with RBC size and rheology, at fixed hematocrit (RBC volume fraction in 
blood), and this variation can affect the binding density/trend of particles since the proper 
ratio of particle size to CFL width is necessary for the optimal particle binding. 
Additionally, plasma compositions also appear to affect the trend of particle adhesion in 
different animal species. Overall, this work sheds light on the potential deviation of 
results investigated in vivo by utilizing animal models from what might be the expected 
outcome in human. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents of this chapter are prepared for submission as Charoenphol P, Namdee K and Eniola-Adefeso O. 
Effect of hemorheology on the binding efficacy of spherical vascular-targeted drug carrier. 
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6.1 Introduction 
To date, vascular-targeted drug delivery has gained tremendous interest for use as 
alternative treatment for several diseases.  To this end, several works have focused on 
characterizing the capacity for vascular-targeted drug carriers (VTDCs) to adhere vividly 
at the targeted sites either via various static in vitro assays [1], flow chamber assays 
ranging in complexity from buffer to blood flows [2, 3], and various animal models of 
human diseases [4, 5]. In vivo assays are preferentially used due to challenges associated 
with recreating the complexity of human body with in vitro assays and since the over-
interpretation of results may lead to failure of VTDCs in human. Animals prominently 
used in drug delivery research include rodents, rabbits, pigs, dogs and monkeys [6-9].  
However, many of these animal species have different blood flow environments and 
hemorheology from human, e.g. differences in shear rates, plasma protein compositions 
that affect blood viscosity and red blood cell (RBC) aggregation, and more importantly 
blood cell properties (i.e. size, shape and deformability), that may limit the extrapolation 
of the generated data to human physiology [10].  These would be of particular importance 
for drug delivery application to diseases typically associated with or affecting medium 
and large blood vessels, e.g. atherosclerosis, where VTDCs must navigate in bulk blood 
flow where the hemorheology effect on VTDC localization and adhesion would be 
prominent.  
Indeed, we recently reported that human RBCs have a significant influence on the 
binding efficiency of spherical particles to the inflamed endothelial cells (ECs) under 
physiological bulk blood flow via in vitro flow assays [2, 11]. We show that small 
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microspheres exhibit a high capacity to marginate (localize and adhere) to inflamed 
human ECs at the wall from steady and disturbed human blood flow, while nanospheres 
and large microspheres exhibit limited margination due to interactions with RBCs and 
high shear, respectively.  The observed size effect on the margination of spheres could be 
explained by the well-documented preferential migration of RBCs away from the wall 
and alignment at the center of the flow while creating a RBC-free layer (CFL) at the wall 
proximity.  This movement of RBCs causes microspheres (as well as leukocytes and 
platelets) in blood flow to concentrate in the CFL via exclusion, enhancing their collision 
and contact with the vascular wall. Additionally, the RBC core imparts a normal acting 
force that, depending on the CFL height to sphere size ratio, helps stabilize adhesion of 
these particles [12]. A significant fraction of nanospheres in bulk blood flow, however, is 
entrapped within the RBC core resulting in their low margination – i.e. they exhibit a low 
capacity to localize to the CFL. The low margination exhibited by larger microspheres (> 
5 µm) is due to high disruptive forces acting to prevent adhesion and the negative impact 
of RBC collision at the wall that destabilizes adhesion.  
The CFL width has been reported to vary from 2.5 - 7 µm in humans and some 
small animals depending on the hydrodynamic shear rate of flow, vessel size, the volume 
fraction of RBC or percent hematocrit (% Hct), and the aggregability and deformability 
of the RBCs [13-17]. Therefore, the subtle differences in the physical properties of RBCs 
among various animal models that possibly result in their differential lateral migration 
and hence the formation of CFL of various extents may eventually lead to variations in 
particle behavior and margination in different animal models.   For example, the volume, 
and aggregability of RBCs in mouse blood, a common animal species used for vascular-
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targeting research, are significantly smaller/lower than in humans [10, 18].  Similar 
variations in RBCs/blood characteristics between human and other common laboratory 
animals prominent in drug delivery research have been reported, including for pigs, 
rabbits, dogs and monkeys.  Yet, to date, very limited works have investigated the impact 
of variations between animal models and human hemorheology on the hemodynamics of 
cells and particles as it relates to their margination to the vascular wall.  The few works 
that exist have primarily focused on platelet adhesion in high shear laminar flow – 
Grabowski et al. found differences in platelet adhesion in whole blood flow of different 
mammalian species via controlled in vitro assays [19], and Aarts et al. observed via flow 
assays with RBCs of various animals that the adhesion of human platelet increased with 
increasing RBC sizes [20].  It is not clear whether this observed effect of RBC size on 
platelet adhesion would hold for the margination of VTDCs of different sizes, 
particularly in the nano-size range. 
This study aims to elucidate the role of RBC dimension coupled with other blood 
components on dictating the binding efficiency of spherical particles sized from 200 nm 
to 5 µm in blood flow. Specifically, the adhesion of inflammation-targeted polystyrene 
spheres to inflamed endothelial cells from flow of washed blood (RBCs suspended in 
saline at fixed 40 % Hct) from different animals and from human and mouse whole blood 
flow were observed via a parallel plate flow chamber (PPFC) under physiological flow. 
Overall, our results show that the capacity of VTDCs to marginate to the vascular wall is 
significantly influenced by blood components, flow types and most importantly, RBC 
size.   
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6.2 Results 
The experimental set up used in this chapter is described in detail in Chapter 2. 
 
 
6.2.1 Effect of RBC size on particle adhesion in washed blood flow 
To study the effect of red blood cell (RBC) size (diameter and volume) on the 
localization and adhesion of vascular-targeted drug carriers to the vessel wall, the binding 
of sLeA -coated spherical particles, 0.2, 0.5, 2 and 5 µm diameter, to inflamed endothelial 
cells in laminar, pulsatile and recirculating human, pig, cow, mouse and goat washed 
blood (RBC in buffer at 40% Hct) flow were observed in a PPFC. The diameters and 
volumes of the different animal RBCs used are summarized in Table 6.1 and the RBC 
morphology observed under a light microscope is shown in Fig. 6.1. 
 
Species Diameter 
(µm) 
Volume 
(µm3) 
Ratio of Volume to 
Diameter (µm2) 
Human 8 90 11.25 
Pig 7.0 58 8.3 
Cow 5.8 58 10 
Mouse 6.8 48 7.1 
Goat 4 18  4.5  
Table 6.1 Red blood cell size of human and different animal species. 
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Figure 6.1 Morphology of (A) human, (B) pig, (C) cow, (D) mouse and (E) goat red 
blood cells suspended in saline under light microscope at 20x magnification.  
A 
B C 
D E 
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Fig. 6.2 shows the particle binding densities observed in laminar washed blood 
flow at wall shear rates (WSRs) of 200 and 500 s-1. At 200 s-1 of laminar human washed 
blood flow, particle adhesion density increased as their diameter increased from 0.2 to 5 
µm while the binding densities of 0.5, 2 and 5 µm spheres in pig, cow and mouse washed 
blood flow, were not significantly different from each other.  The 0.2 µm sized spheres 
displayed minimal binding in laminar washed blood flow for all species (Fig. 6.2A). At 
500 s-1, the adhesion densities of microspheres (2 and 5 µm) in human washed blood was 
significantly increased relative to their adhesion at 200 s-1 with 5 µm spheres displaying 
the highest adhesion (Fig. 6.2B). The binding of nanospheres was not affected by this 
magnitude of change in WSR, resulting in greater differences between the binding 
density of microspheres and nanospheres in human washed blood at the higher WSR (500 
s-1). In contrast, the increase in WSR to 500 s-1 enhanced the binding density of particles 
of all sizes in pig, cow and mouse washed blood, though the increase in the adhesion of 
0.5 µm spheres binding was not significant in all animal species (Fig. 6.2B). Overall, at 
WSR 500 s-1, microsphere binding was significantly higher relative to nanospheres and 
no significant differences were observed between the binding of the two microspheres 
(between 2 and 5 µm) in pig, cow and mouse washed blood flow (Fig. 6.2B). 
Furthermore, there was no significant difference between the adhesion density in mouse 
and goat laminar washed blood at WSR 500 s-1 for nanospheres and 2 µm spheres while 5 
µm spheres exhibited lower adhesion in goat blood (Fig. 6.2B).    
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Figure 6.2 Adhesion of sLeA-particles in human, pig, cow, mouse and goat laminar 
washed blood flow at WSR (A) 200 s-1 and (B) 500 s-1.  
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In an attempt to speculate on the correlation between particle adhesion and RBC size, the 
binding density of spheres in laminar washed blood flow at WSR 500 s-1 were replotted 
as a function of RBC diameter, RBC volume and the ratio of RBC volume to diameter. 
As shown in Fig. 6.3A, the adhesion trend of particles particularly microspheres did not 
show an explicit correlation with RBC diameter since a large difference in the binding 
density of both 2 and 5 µm spheres were observed between pig and mouse washed blood 
flow despite these two species having comparable RBC diameters. However, particle 
adhesion appear to be a function of RBC volume as shown in Fig. 6.3B. Specifically, the 
binding of 0.2 µm spheres slightly decreased with increasing RBC volume whereas the 
binding of 5 µm spheres linearly increased (slope = 4.2) as RBC volume increased. The 
adhesion of 0.5 and 2 µm spheres increased with increasing RBC volume reaching an 
optimal binding at RBC volume of 58 µm3 (i.e. cow and pig washed blood) and 
decreased as RBC volume further increased. To tease out the couple effect of RBC 
diameter and volume, the particle binding density was replotted against the ratio of RBC 
volume to diameter (Fig. 6.3C). Overall, the correlation of particle binding to this ratio 
was similar to the one observed with RBC volume. 
 The binding trend observed for particles in pulsatile washed blood flow (profile 
II, pulsed only in the forward direction between low (120 s-1) and high WSR (1200 s-1)), 
was similar to observation in laminar flow at WSR 500 s-1. As shown in Fig. 6.4A, the 
adhesion of microspheres was significantly higher than nanospheres in human, pig and 
mouse washed blood. In each species, the binding density increased as particle size 
increased from 0.2 to 2 µm while no significant difference was observed between the 
binding density of 2 and 5 µm spheres.   
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Figure 6.3 Adhesion of sLeA-particles in human, pig, cow, mouse and goat laminar 
washed blood flow at WSR 500 s-1 as a function of (A) RBC diameter, (B) 
RBC volume and (C) the ratio of RBC volume to diameter. 
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Figure 6.4 (A) Adhesion of sLeA-particles in human, pig, cow, mouse and goat pulsatile 
washed blood flow (pulsatile profile II, pulsed between WSR 120 s-1 and 1200 
s-1). Total time = 5 mins. Particle binding was plotted as a function of (B) 
RBC diameter and (C) the ratio of RBC volume to diameter.   
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In contrast, in cow pulsatile washed blood, the particle adhesion was similar to their 
binding trends in laminar flow at WSR 200 s-1. Specifically, there was no significant 
difference in the binding density of 0.5, 2 and 5 µm spheres, while the adhesion of 0.2 µm 
particle was minimal relative to other sizes. Overall, the binding density of microspheres 
(2 and 5 µm) in human pulsatile blood flow is significantly higher relative to other animal 
bloods while nanospheres (200 and 500 nm) showed the optimal binding in cow pulsatile 
washed blood (Fig. 6.4A). The particle binding in pulsatile washed blood flow appeared 
to be a function of RBC diameter, which we did not observe in laminar washed blood 
flow (Fig 6.4B). Specifically, the binding density of nanospheres linearly decreased as 
RBC diameter increased with slope -17.2 and -54.2 for 0.2 and 0.5 µm spheres, 
respectively, suggesting that the capacity for 0.5 µm spheres to bind in pulsatile flow is 
more susceptible to the change of RBC diameter relative to 0.2 µm particles. Again, there 
is no obvious correlation between the microsphere binding density in pulsatile flow and 
RBC diameter, though their binding decreased as RBC diameter increased reaching a 
minimum point at 7 µm of RBC diameter (i.e. pig washed blood). Beyond this point, the 
microsphere binding increased with increase in RBC diameter. Fig. 6.4C shows the 
particle binding plotted with the ratio of RBC volume and diameter. The nanosphere 
binding increased as the ratio increased peaking with the ratio of 10 that correlates to cow 
washed blood and significantly dropped as the ratio increased while the binding of 
microspheres slightly fluctuated as the ratio of RBC volume to diameter increased from 7 
to 10 prior to rise as the ratio increased to 11.25 (i.e. human washed blood). The binding 
densities of microspheres were correlated with the ratio of RBC volume to diameter with 
the 2nd order polynomial curve.  
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For recirculating washed blood flow in the VSFC, particle binding was plotted 
with distance from the vertical step toward far downstream where laminar flow (WSR = 
200 s-1) was re-established. In general, the binding density of spheres in human washed 
blood was a function of particle size, where 5 µm exhibited the optimal adhesion as 
shown in Fig. 6.5A. The binding density of microspheres (2 and 5 µm) increased with the 
distance away from the step reaching their peak binding at distances slightly beyond the 
reattachment point (~ 170 µm from the step). Beyond this point, the binding density of 2 
µm spheres plateaued while the adhesion of 5 µm spheres decreased toward far 
downstream. There was no significant difference measured for the binding of 2 and 5 µm 
particles at far downstream.  Nanosphere binding in human washed blood in the VSFC, 
however, did not show any obvious peak and was not significantly different from each 
other in both recirculating and far downstream area (Fig. 6.5A). In pig washed blood, the 
binding density of spheres similarly increased as their diameter increased from 0.5 to 5 
µm in the recirculating area. At far downstream, no significant difference was observed 
between the binding density of nanospheres and 2 µm particles while 5 µm spheres 
exhibited the optimal binding (Fig. 6.5B). Overall, the adhesion of 5 µm spheres in pig 
recirculating washed blood flow decreased while the binding of other sphere sizes was 
unchanged relative to their binding densities in human blood. Particle binding in mouse 
recirculating washed blood was similar to the one observed in human and pig washed 
blood where the binding density of spheres increased as particle size increased from 0.5 
to 5 µm, though the adhesion of 2 and 5 µm was only significantly different from each 
other at the peak binding near the reattachment point (Fig. 6.5D).   
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Figure 6.5 Adhesion of sLeA particle in recirculating washed blood flow with (A) 
human, (B) pig, (C) cow and (D) mouse red blood cells at WSR 200 s-1 of 
far downstream.  
Dash line represents observed reattachment point.  
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There was no significant difference between nanosphere binding in all region of the 
VSFC in mouse washed blood. In addition, the adhesion density of microspheres in 
mouse recirculating washed blood was surprisingly slightly higher than the ones in 
human recirculating washed blood flow which was in contrast to the lower microsphere 
binding observed in mouse laminar and pulsatile washed blood flow. In cow washed 
blood, the 5 µm particle binding in the VSFC decreased such that their binding density 
was lower than the binding level of 2 µm particles unlike observation with other species 
blood. Nevertheless, the binding density of microspheres in cow washed bloods was still 
higher than nanospheres in the VSFC, similar to the particle binding trend observed in 
other species (Fig. 6.5C). 
Fig. 6.6 shows the particle binding density replotted from Fig. 6.5 as a function of 
particle size. Overall, the binding of nanospheres in recirculating washed blood did not 
depend on RBC size, i.e. the species.  The adhesion of 2 µm spheres in cow and mouse 
washed blood was significantly different from the ones in human and pig washed blood 
only at 600-700 µm from the step  (Fig. 6.6C). Spheres with 5 µm diameter exhibited 
significantly higher binding in human and mouse washed blood than in cow and pig 
washed bloods only at their peak adhesion (Fig. 6.6D). The binding densities of 0.5, 2 
and 5 µm spheres at the peak adhesion (~ 500 µm from the step) showed trends with the 
ratio of RBC volume to RBC diameter where the particle binding decreased as the ratio 
increased reaching minimal bindings and the binding densities increased again as the 
ratio increased beyond the minimum point. No obvious correlation between the binding 
of 0.2 µm spheres and RBC morphology has been observed in recirculating washed blood 
flow (data not shown).  
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Figure 6.6 Adhesion of sLeA particle (A) 0.2 µm, (B) 0.5 µm (C) 2 µm and (D) 5 µm in 
recirculating washed blood flow of human and animal red blood cells with 
WSR 200 s-1 at far downstream.  
Dash line represents observed reattachment point.  
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6.2.2 Particle binding in human and mouse whole blood flow 
 To probe for the contribution of other blood cells and plasma constituents, spheres 
of different sizes were observed for their binding in human and mouse whole blood flow. 
Though human and mouse whole blood were collected in different anticoagulants i.e. 
ACD and heparin, respectively, no significant difference was observed on particle 
adhesion in human whole blood containing ACD or heparin, which suggested that 
anticoagulant may have minimal effect on particle binding in this study. Additionally, I 
showed that the introduction of mouse whole blood over human endothelial cells did not 
affect the human cell functionality as confirmed by observation of the similar binding 
density of spheres from human whole blood on the fresh human cell monolayers and the 
one that was pre-exposed with mouse whole blood flow for 5 min (data not shown). Fig. 
6.7 shows the binding density of spheres in laminar whole blood flow at WSR 200 s-1 to 
1000 s-1. Overall, particle adhesion in human whole blood was similar to observation in 
human washed blood where microspheres (2 and 5 µm) binding was significantly higher 
than nanospheres at all shear rates studied; however, 2 µm spheres exhibited the peak 
adhesion in whole blood, which was likely due to the slight higher % Hct in human 
whole blood and as discussed in Chapter 5. Conversely, in mouse whole blood, the 0.5 
and 2 µm spheres displayed the optimal binding depending on the magnitude of the WSR 
whereas 5 µm spheres had minimal binding at all shear rates, which is contradictory with 
the binding trends observed in washed blood. When comparing the binding density 
between these two species, the 0.5 µm spheres showed higher adhesion in laminar mouse 
whole blood flow relative to human whole blood by ~ 2.5-3 folds.   
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Figure 6.7 Adhesion of sLeA-particles in human and mouse laminar whole blood flow at 
WSR (A) 200, (B) 500 and (C) 1000 s-1.  
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There were no significant differences in the binding of 2 µm particles besides at WSR 
1000 s-1 where the adhesion in human whole blood was ~ 2 folds higher. Interestingly, 
the differences in 5 µm binding density between these two species increased as WSR 
increased. Specifically, the binding in human whole blood was ~ 3-24 folds higher than 
the one in mouse whole blood as the shear rate increased from 200 to 1000 s-1. 
Fig. 6.8 shows particle binding in pulsatile whole blood flow (profile I) pulsed in 
the backward and forward direction with a peak WSR at 1000 s-1. The particle binding 
trends of sLeA-spheres in pulsatile whole blood flow was similar to the one observed in 
laminar whole blood flow, where 2 and 5 µm particles displayed the higher binding than 
nanospheres in human whole blood and 0.5 and 2 µm spheres exhibited higher adhesion 
in mouse whole blood than 5 µm spheres, which again was contradictory to the pattern of 
particle binding in mouse pulsatile washed blood. To study whether the significant 
difference of the binding trends observed in mouse whole blood versus washed blood was 
due to contributions from mouse plasma components, spheres of different sizes were 
observed for their binding in plasma-removed blood in pulsatile flow. As shown in Fig. 
6.8, the binding density of microspheres (2 and 5 µm) in human plasma-removed blood 
was lower relative to whole blood while 0.5 µm spheres displayed the same level of 
adhesion in the presence or absence of plasma. The removal of plasma from mouse blood 
decreased the binding density of nanospheres (0.5 µm) whereas mouse plasma had no 
effect on microsphere binding.  
Fig. 6.9 shows the binding of sLeA- spheres from human and mouse whole blood 
in the VSFC.   
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Figure 6.8 Adhesion of sLeA- particles in pulsatile human and mouse (A) whole blood 
flow and (B) plasma removed blood at WSR 1000 s-1 for 5 min.  
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Figure 6.9 Adhesion of sLeA –particles (1000 sLeA site/µm2) in recirculating (A) human 
and (B) mouse whole blood flow at WSR 200 s-1.  
Dash line represents observed reattachment point.  
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The sLeA-particle binding pattern in human whole blood was similar to the one seen in 
human washed blood where microspheres displayed significantly higher binding relative 
to nanospheres, though the binding densities for all particle sizes significantly increased 
in human whole blood relative to human washed blood (Fig. 6.9A). In mouse 
recirculating whole blood, the adhesion of 0.5 and 2 µm sLeA-spheres were significantly 
enhanced relative to their binding in mouse recirculating washed blood while the binding 
of 5 µm spheres was unchanged. Overall, 2 µm sLeA-spheres displayed the optimal 
adhesion in mouse recirculating whole blood (Fig. 6.9B) while 5 µm sLeA spheres remain 
optimal in mouse washed blood. 
 
6.3 Discussion 
Due to many advantages gained from utilizing imaging modalities and vascular-
targeted drug delivery in the early diagnosis and treatment of diseases, several research 
work have been focused on the design and engineering of the optimal vascular-targeted 
carriers for use to localize contrast and/or therapeutic agents to a target site in several 
human diseases, including in cancer and cardiovascular diseases.  To ensure the in vivo 
functionality of designed delivery system, most researchers utilize animal models of 
human diseases, and this primarily represents the core of preclinical research prior to 
advancement to clinical testing.  Mouse, rat, rabbit, pig, dog and monkey models are 
extensively used for testing in the preclinical research relating to vascular-targeting [6-9], 
despite the significant differences in blood rheology, hemodynamics and the vasculature 
structure of these animals relative to human [10, 18, 22, 23]. Though, the potential 
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correlation and the suggested scaling factor of a particular animal to human, respective to 
their differences in macroscopic scale, i.e. shear stress, are available [22, 23], limited 
works have studied the potential implications of the variations in microscopic scale, 
including different size of blood cells and plasma constituents, on the efficiency of 
vascular-targeted drug delivery relative to human physiology. Due to the significant 
influence of RBCs and other blood cells on particle margination in blood flow as 
thoroughly described in the previous chapters, it is likely that the distinct hemorheology 
that exists in animal models relative to humans, particularly the difference of red blood 
cell (RBC) size, can result in the differential pattern of targeted carrier localization and 
adhesion (margination) of particles of various sizes to the vascular wall. Herein, the 
adhesion of sLeA- coated particles, 0.2, 0.5, 2 and 5 µm in diameter, to the inflamed 
endothelial cells in flow of human, pig, cow, mouse and goat washed blood (40% Hct 
RBCs suspended in saline) and whole blood was observed in vitro via a parallel plate 
flow chamber (PPFC) assays with physiological shear conditions. Overall, the presented 
results showed that the binding efficiency of sLeA-particles varies with the dimension of 
RBCs corresponding to different animal models and flow types. I also suggested that the 
ratio of particle to red blood cell size has significant influences on the margination of 
vascular-targeted carriers in blood flow. 
For instances, at WSR 500 s-1 of laminar flow, the binding density of 0.5 µm 
spheres in pig and cow washed blood were significantly higher relative to other species 
whereas 5 µm spheres exhibited the optimal binding in human washed blood. The 
discrepancies in the particle binding density are likely due to different sizes of their 
RBCs; however, it is not clear how differences in RBC dimension can alter particle 
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localization and adhesion to the wall. Since these adhesion experiments were observed at 
fixed RBC volume fraction (at 40% Hct); therefore, a larger number of RBCs with 
smaller volume as it is for pig and cow RBCs, relative to human, would be required to 
yield the same hematocrit in the same blood volume. However, under the same flow 
conditions, the large number of small RBCs is likely to be packed similarly to the low 
number of large RBCs, as shown in their equivalent RBC packing height during the step 
of %Hct measurement via centrifugation (see Chapter 2). This equivalent RBC packing 
suggests that these RBCs may similarly align under shear flow resulting in equivalent cell 
free layer (CFL) widths at the vascular wall proximity, which eventually leads to the 
comparable binding density of spheres at a given particle size. However, my 
experimental data showed conflicting results where different particle binding densities for 
a given particle size were observed in various species suggesting that CFL width might 
be varied among animal models. It is possible that the higher number of small RBCs as in 
mouse and goat blood may cause frequent collisions and intensified hydrodynamic 
interactions among RBCs that tend to expand the RBC core, i.e. CFL width decreases 
[24].  Additionally, RBC deformability is known to strongly affect the alignment of 
RBCs under shear flow, i.e. deformable RBCs tend to migrate to the center of flow while 
rigid RBCs, less susceptible to the shear flow, are likely to stay adjacent to the wall [17]. 
Since small-sized RBCs are likely to be less susceptible to deformation under shear force, 
i.e. lower “apparent” deformability, due to their small surface area, relative to large-size 
RBCs; therefore, small RBCs are likely to exhibit low migration to the center of flow 
resulting in the smaller CFL width. This agrees well with my first hypothesis. 
Accordingly, the binding of nanospheres (0.5 µm) in the smaller CFL (in pig and cow 
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blood) likely increased due to the increase in particle-wall collisions and the impact of 
normal force from RBC core that enhanced and stabilized their adhesion, as observed in 
laminar flow at WSR 500 s-1 [12]. However, a shrinking of plasma CFL would lead to a 
higher packing of larger spheres (5 µm) and excessive collision among particles that can 
hinder the particle binding as observed in low binding of 5 µm spheres in pig and cow 
laminar washed blood. The lower binding densities of 2 and 5 µm spheres in mouse and 
goat (having the smaller RBC volume relative to pig and cow) laminar washed blood 
(WSR 500 s-1) further verified these explanations.  
Overall, the adhesion density displayed by spheres of a given size in laminar 
washed blood flow at WSR of 500 s-1 appears to be a strong function of RBC volume for 
the spheres with diameter greater than 0.2 µm as shown in Fig. 6.3B. The disconnection 
in the adhesion density obtained for spheres between pig and mouse washed blood with 
approximately the same diameter would suggest that the RBC diameter plays a minimal 
role in carrier adhesion though the clearer adhesion trend seen in the plot of particle 
adhesion density versus RBC volume to diameter ratio in Fig. 6.3C would suggest some 
minimal dependence on RBC diameter. The strong dependence of particle binding on 
RBC volume may again be related to the characteristics of the CFL generated.  
Specifically, the low capacity of 0.5 and 2 µm sphere binding observed in mouse and 
goat washed blood that have smaller RBC volumes may be due to non-existence or 
narrow CFL formed at fixed hematocrits such that the presence of RBCs at the wall 
proximity disturb and negatively affect the adhesion of particles at the wall. As the RBC 
volume increases to the certain ranges where these RBCs form the wider CFL width 
allowing particles to localize to the wall, the accumulation of particles in the CFL 
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enhances collision among particles and/or with RBCs leading to the increase in particle 
binding as seen in pig and cow washed blood. Beyond the optimal RBC volume, the 
binding of particles decreases again due to the larger CFL width where the normal force 
imparted by RBC and the collision among particles have a minimal effect on promoting 
particle adhesion to the wall. On the other hand, 5 µm spherical diameter is in line with 
the maximum CFL height range that commonly existing in human physiological 
conditions (2.5-7 µm) [13, 14], thus, the further decrease in CFL width as the RBC 
volume gets smaller would tend to negatively effect the binding of large microspheres. 
The lack of a RBC volume effect (i.e. the effect of CFL width) on the adhesion of 0.2 µm 
spheres is likely due to their extremely poor localization to the wall and their small size 
relative to the CFL width [2, 11].  
The particle binding in human, pig and mouse pulsatile washed blood flow was 
similar to observation in laminar flow at WSR 500 s-1 where the adhesion of 
microspheres was favored over that of nanospheres. No significant difference was 
observed between the binding density of the two microspheres evaluated (2 and 5 µm) in 
pulsatile washed blood flow (Fig. 6.4), The slight decrease in the binding density of 5 µm 
spheres relative to 2 µm spheres in human washed blood is likely due to the high slip 
velocity (i.e. the velocity of particle before forming a single bond at the wall) that 5 µm 
spheres experience at high shear during the peak WSR of pulsatile flow [2]. The higher 
binding of 0.5 µm particles in pig and mouse washed bloods relative to human could 
again be explained by the smaller CFL width of the former. Since the CFL width 
becomes smaller as WSR increases, at fixed hematocrit and channel height [21], the 
combination of small RBC size and the increase in WSR in pulsatile flow can further 
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shrink the CFL width resulting in the lower binding of large microspheres (2 and 5 µm) 
observed in pig and mouse blood. Overall, there was no significant difference between 
the particle binding density in pig and mouse pulsatile washed blood flow likely due to 
their similar RBC diameter. Though the volume of pig and cow RBCs are similar, the 
difference in nanosphere binding density seen in pulsatile flow suggested that RBC 
diameter significantly contribute to particle binding in pulsatile flow as observed by the 
increase in nanosphere binding with decreasing RBC diameter (Fig. 6.4B). The rotation 
of RBCs in pulsing flow, that would be RBC diameter dependent, may disturb the 
packing of RBC and hence the formation of the CFL.  
In general, the binding of nanoparticles in recirculating washed blood flow (WSR 
= 200 -1) was minimal for all species and no significant differences among various species 
were observed, likely due to the extremely poor localization of nanospheres to the wall in 
this flow type, as suggested in the previous chapters (Fig. 6.6A and 6.6B). Spheres with 2 
and 5 µm diameters exhibited the optimal binding in mouse/cow and human recirculating 
washed blood flow, respectively, particularly at the peak adhesion probably due to large 
accumulation of microspheres brought along with the vortex streamline at the 
reattachment point. In addition, the optimal RBC size forms the proper CFL width 
beyond the reattachment point also enhance the microsphere binding (Fig. 6.6C and 
6.6D). No explicit correlation between the particle binding and RBC morphology was 
observed in recirculating flow for spheres with 0.2, 0.5 and 2 µm diameters, probably due 
to the flow complexity that redistributes the RBCs and particles in the vortex and far 
downstream as suggested in Chapter 4, though the 2nd order polynomial curve fitted well 
between the binding density of 5 µm spheres and the ratio of RBC volume to diameter.  
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In general, the pattern of sLeA-particle binding in all flow types of human whole 
blood was similar to observation in human washed blood where microspheres exhibited 
the higher binding than nanospheres.  However, the sLeA-particle binding trends in 
mouse whole blood were significantly different from mouse washed blood, particularly 
the minimal binding of 5 µm spheres observed in mouse laminar whole blood flow. The 
slightly higher binding of 5 µm over 0.5 µm-sLeA spheres near the reattachment point of 
recirculating mouse whole blood flow may be due to the large gain of 5 µm localization 
to the wall in this flow type (Fig. 6.9B). Overall, the discrepancies of particle binding in 
laminar mouse washed and whole blood flow suggested that plasma induced aggregation 
properties might have a strong impact on the particle behavior in blood flow since all 
other blood cells were present in the washed blood experiments for mice (see Chapter 2).  
To probe the effect of plasma on particle behavior, the adhesion of spherical particles was 
observed in plasma-removed blood in pulsatile flow (Fig. 6.8). Overall, removing plasma 
from human whole blood resulted in the reduction of microspheres (2 and 5 µm) 
adhesion likely due to the absence of cell free layer (CFL) at low WSR of pulsatile flow, 
as large protein molecules in plasma are necessary for bridging human RBCs to form 
aggregates at the flow center [25]. Conversely, there were no changes in microsphere 
binding in mouse plasma-removed blood relative to whole blood while the binding 
density of 0.5 µm particles decreased to the similar binding level as observed in human 
whole blood when mouse plasma was removed (Fig. 6.8). However, the decrease in 
nanosphere binding in mouse plasma-removed blood may not be due to the absence of 
CFL at low WSR as seen in human blood since mouse RBC does not aggregate under 
low WSR [10]. Additionally, the binding of 5 µm spheres did not gain back as the mouse 
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plasma was removed possibly due to the excess plasma left during the removal step (see 
Chapter 2) that may interfere their adhesion. Overall, This result suggested that mouse 
plasma compositions could play a significant role on particle binding; however, further 
detailed studies are needed for clarification.  
Overall, though this work has not fully elucidated the understanding in different 
trends of particle binding observed in several animal models commonly used in the 
preclinical research, our findings addressed many important factors including the effect 
of RBC size and other blood cells that can affect the binding efficiency of vascular-
targeted carriers. This study also raises the awareness of potential deviation of results 
investigated in vivo and the expected outcome in human, which is an important message 
to many research fields.   
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CHAPTER 7  
 
CONCLUSIONS AND FUTURE WORKS 
 
 
7.1 Conclusions and Significant Contributions 
To date, vascular-targeted drug delivery remains attractive interest for localized 
delivery of therapeutics, encapsulated in a carrier, to the specific diseased targets. This 
process offers high drug efficacy at the target sites while minimizing drug side effects 
associated with other healthy tissues. Due to these advantages over the traditional 
therapies, vascular-targeted drug delivery can be used as an alternative treatment for 
many serious diseases, including cancer, pulmonary and cardiovascular diseases – the 
leading cause of death in the world. To design the optimal drug carrier for vascular-
targeted drug delivery, there are three important criteria that need to be considered, i.e. 
targeting, physical and hemodynamics properties. Firstly, the targeting specificity of drug 
carrier can be achieved by modifying the carrier surface with ligands having a specific 
binding affinity with the target sites. In this study, it appears that sialyl-lewis A (sLeA), a 
carbohydrate ligand for selectins, is suitable for use on vascular-targeted drug carriers 
(VTDC) in targeting the inflamed tissues. My results showed that sLeA-coated particle is 
not only able to selectively target the intended sites but also effectively captured under 
high shear flow at the similar rate as the leukocyte binding. However, the drawback of 
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this sLeA-particle is its weak adhesive force, in which particle, particularly large 
microspheres, can simply detach once adherence under high shear flow and/or by the 
addition of drag force associated with leukocyte rolling motion, as discussed in Chapter 3 
and 5. Therefore, decorating the surface of VTDC with dual-targeted ligands, i.e. both 
sLeA and monoclonal antibody (aICAM or aVCAM), at the optimal ligand ratio may be a 
better carrier model for future works in effectively targeting the vascular wall with high 
binding efficiency. Specifically, sLeA molecules assist in capturing particle to the 
vascular wall under shear flow, while antibody molecules help particle to withstand the 
high shear force and remain adherence.  
As discussed in Chapter 3 and 4, prior to their selectively binding at the targeted 
sites, the VTDCs must be able to localize through the bulk blood flow to the wall 
proximity. The physical properties of drug carrier, hemodynamics, and the structure of 
vasculature, have been shown to significantly govern the localization of VTDC in blood 
flow. My results indicate that wall shear rate (WSR) and the size of blood vessel affect 
the behavior of VTDC in both buffer and blood flow. Specifically, the normalized 
particle binding density decreases as WSR and channel height increase, due to high 
particle slip velocity encountered at high WSR or in large channel. Additionally, the 
presence of RBCs enhances the localization and adhesion of particles for all sizes, 
especially microspheres, by aligning at the center of flow and creating the cell free layer 
(CFL) at the wall vicinity. The migration of RBCs away from the vascular wall causes 
the lateral displacement of particle into the CFL area, which increases their opportunity 
for interaction and adhesion at the wall. Since the width of CFL varies with a percent of 
hematocrit, blood vessel size and WSR, the particle binding density also changes with 
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this variation. Indeed, ideally, the optimal ratio of particle size to CFL width would yield 
the maximum particle binding efficiency. Moreover, my results demonstrated that flow 
types could affect particle behavior in blood flow. Specifically, the increase of residence 
time along with average low shear force (i.e. lower particle slip velocity) in pulsatile flow 
can promote the binding of particles relative to laminar flow. Recirculating flow also 
redistributes and localizes particle, particularly microspheres, to the wall near the 
reattachment point due to the presence of maximal normal velocity interacting toward the 
vessel wall and minimal axial velocity. Overall, this work provides in depth 
understanding on drug carrier margination in bulk blood flow and suggests that 2 – 5 µm 
spherical particle, not nanoparticles, are the optimal size for VTDC in targeting the 
vascular wall of medium-to large sized arteries in physiological blood flow. These 
findings are beneficial to vascular-targeted drug delivery and imaging techniques since 
the suggested optimal carrier size can be utilized to effectively deliver medications or 
assisting in early disease diagnosis, which can possibly decrease the mortality in several 
serious diseases. 
 In Chapter 5, the influence of other blood cells, leukocytes (white blood cells) and 
platelets, on particle binding efficiency was discussed. Overall, leukocytes tend to 
prevent and/or compete with the binding of particles particularly microspheres. The 
rolling motion of leukocytes along inflamed endothelium can collide with previously 
adherent particles resulting in the increase of drag force on particle that may overcome 
their adhesive force causing the particle removal. Despite this negative effect of 
leukocytes, microspheres still efficiently target the vascular wall relative to nanospheres 
in physiological whole blood flow. On the other hand, resting platelets present in whole 
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blood has a minimal role on particle adhesion, likely due to their low binding affinity on 
the inflamed endothelium and their physical property that tend to minimize collision.  
Understanding in the role of individual blood cells on prescribing the VTDC binding 
efficiency is valuable since this knowledge allows the flexibility in VTDC design for 
various target sites and/or patients having different blood cell population. 
Last but not least, this study also shed light on the different particle behavior 
observed in animals and human blood, likely due to the variations in RBC rheology and 
other blood cells, as discussed in Chapter 6. For instances, nanoparticles showed 
significantly improved adhesion in mouse whole blood relative to their minimal binding 
in human whole blood. This study raises the awareness of inadequacy in utilizing animal 
models to represent human body.  
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7.2  Future Works 
Though this dissertation has elucidated the role of particle size, hemodynamics, 
and hemorheology which are significant criteria necessary for designing the optimal 
vascular-targeted carriers (VTCs) used in imaging and therapeutic delivery, particularly 
for chronic inflammatory diseases, the investigation in this field could be further 
developed and extended in the following directions. 
 
(1.) Further investigate the potential factors responsible for the different particle binding 
density in human and animal whole blood, previously observed in Chapter 6. 
Specifically, the effect of plasma constituents, RBC rheology and other blood cells 
of various animals on particle binding may need to be revisited and carefully 
examined. 
 
(2.) Develop and/or improve the in vitro flow adhesion assay to resemble the 
physiological conditions as encountered in human.  
(2.1) Since this work focuses on localized delivery of therapeutic agents to 
atherosclerosis, which often occurs in medium to large-sized arteries, thus, 
human arterial endothelial cells (HAEC) co-cultured with smooth muscle cells 
may be more suitable to use as an adhesion substrate in in vitro flow assay. 
Though, human umbilical vein endothelial cells (HUVECs) employed in this 
dissertation is widely used as an in vitro model of inflamed endothelial cells 
lining of blood vessels; however, the pattern and level of receptors expression 
on HAEC and HUVEC during inflammation may be different. In addition, the 
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smooth muscle cells lining underneath arteries endothelium could also effect 
the regulation of receptors. Consequently, the variation of receptor expression 
may impact the binding efficiency of VTCs and their adhesion trend, relative 
to particle size. 
(2.2) Observe the adhesion of VTC at the bifurcation or arterial trees- mimicking 
flow channel, which are the prone site of atherosclerotic plaque formation. 
This study would determine the trend of particle binding and possibly suggest 
the optimal VTC size used for targeting specifically to the plaque area. 
(2.3) The flow adhesion assay could further develop to a 3-dimensional flexible 
tube where particles are allowed to adhere to the surrounded tube wall. 
Though, my study previously suggested that gravity had a minimal role on 
particle adhesion in blood flow; however, the particle binding trend in the 3D 
tube could be different due to various factors including the velocity profile 
that occurred in different coordinating system. Additionally, the tube 
flexibility could affect the adhesive affinity of particle to the endothelial cell 
substrate, which may also alter the particle binding trend. 
 
(3.) Investigate the potential role of biomaterials on particle behavior in blood flow.  
Though polystyrene (PS) polymeric particle, VTCs used in this dissertation, is 
commonly employed for in vitro assays, however, poly (lactic-co-glycolic) acid 
(PLGA) and polycaprolactone (PCL) polymeric particles are preferable for in vivo 
research due to their biodegradability and biocompatibility. This study has 
elucidated the role of PS particle size on dictating the binding efficiency in blood 
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flow; future works need to confirm that other commonly used VTCs including 
PLGA and PCL particles can effectively marginate in physiological blood flow. 
Due to the different properties of these biomaterials such as density and surface 
characteristics, the behavior in blood flow and the interaction with blood cells of 
these particles could be different and thus may effect their binding efficiency.  
 
(4.) Study the fate of vascular-targeted drug carriers (VTDCs) beyond their margination 
to the vascular wall. 
(4.1) Determine the role of particle physical properties, e.g. size, shape and surface 
charge, on dictating the transmigration of VTDC underneath the endothelial 
cells. 
(4.2) Study the mechanism of VTDC degradation and the pathway of drug release 
and delivery into the targeted cells. 
 
(5.)  Design alternative shapes of VTDCs such as rods and discs.  
Though, this study suggests that 2-5 µm spherical particles (not nanospheres) 
are the optimal carrier size for VTDCs; these carriers may not be practically used 
since their size ranges are in line with the size of capillaries (the smallest human 
blood vessels), then having the possibility to clog the blood flow in 
microcirculation. Therefore, to avoid the possible occlusion, the carriers with other 
shapes that can localize from the RBC core, effectively adhere at the vascular wall, 
and easily travel in microcirculation without causing occlusion may be better to use 
as alternative VTDCs.   
